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ABSTRACT 
Background and aim: The role of bone morphogenetic proteins (BMP) 4 and 7 in 
primary breast cancer is peculiar as they are known to induce cell proliferation in some 
tumor cells and also to reduce tumor growth in some cells. They are studied for their 
signaling on gene transcription. Characterizing the transcriptional response of primary 
breast cancer cells to BMP4 and BMP7 would serve better in understanding the role of 
these proteins in cancer biology. This work is aimed at finding out the genes that respond 
to these ligands. The data taken for analysis is an Agilent RNA microarray data. The data 
is produced from RNA of seven breast cancer cell lines that were treated with BMP4 and 
BMP7 ligands. Each cell line had shown different expression to these ligands and hence 
finding the genes that are most significant in their expression when treated with these 
ligands and also exploring the Gene Ontology, Transcription Factor and KEGG 
pathways of these genes would provide more information. These studies were performed 
also for the set of genes obtained from hierarchical clustering known as group C genes.  
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Methods: The Agilent microarray data was analyzed using Bioconductor’s limma 
package in R programming environment. The cell lines that were treated with both 
BMP4 and BMP7 and that were treated only with BMP4 were analyzed separately. The 
significant genes were found out based on P-value and heat maps were generated using 
the log FC (Fold Change) values revealing their expression upon BMP4, BMP7 
treatments. Furthermore, using WebGestalt the Gene Ontology, Transcription Factor and 
KEGG pathways were also analyzed. The group C genes were also subjected to these 
analyses using WebGestalt.     
Results: In BMP4 and 7 treated cell lines, there were ninety three genes showing 
varying expression and for BMP4 treatment there were eighty one genes that showed 
expression. The genes showed over expression or up regulation and under expression or 
down regulation in each cell line indicating the influence of BMP4 and BMP7 signaling. 
The KEGG pathways like cancer and melanoma indicated the importance of genes and 
signaling of ligand molecules in cancer.  
Conclusion: The aim of the thesis work was to identify the set of genes regulated by 
BMP4 and BMP7 signaling and it was obtained. It can be said that the BMP4 and BMP7 
had a strong effect on the genes by varying their expression from each cell line to the 
other. The work had established basic information on signaling effects of BMP4, 7. It 
had also found out the biological and molecular functions, transcription factors and 
KEGG pathways involving these genes.  
 
 
  
vi 
 
CONTENTS 
1. INTRODUCTION .......................................................................................................... 1 
2. REVIEW OF LITERATURE ......................................................................................... 4 
2.1 Breast cancer – An overview .................................................................................... 4 
2.1.1 Breast cancer and its types ................................................................................. 4 
2.1.2 Epidemiology of breast cancer ........................................................................... 5  
2.1.3 Genes associated with breast cancer .................................................................. 6 
2.2 BMP and SMAD pathways ...................................................................................... 7 
2.2.1 BMP Signaling pathway .................................................................................... 9  
2.3 Role of BMPs in breast cancer ............................................................................... 11 
2.4 Role of BMP4 and BMP7 in breast cancer ............................................................. 13 
2.5 DNA and RNA Microarrays and its applications in Gene Expression Profiling ... 17 
3. OBJECTIVES .............................................................................................................. 22 
4. MATERIALS AND METHODS ................................................................................. 23 
4.1 MATERIALS ......................................................................................................... 23 
4.1.1 Microarray data ................................................................................................ 23 
4.1.2 Hierarchically clustered group C genes ........................................................... 24 
4.1.3 Tools used for analysis of Microarray data ...................................................... 24 
4.1.4 WEB-based GEne SeT AnaLysis Toolkit ........................................................ 25 
4.2 METHODS ............................................................................................................. 25 
4.2.1 Analysis of cell lines treated with both BMP4 and BMP7 .............................. 26 
4.2.2 Analysis of cell lines treated only with BMP4 ................................................ 27 
4.2.3 Gene Ontology, Transcription Factor, KEGG pathway analysis of cell lines 
treated with both BMP4 and BMP7 and only with BMP4 ....................................... 27 
4.2.4 Gene Ontology, Transcription Factor, KEGG pathway analysis of group C 
genes ......................................................................................................................... 29 
5. RESULTS ..................................................................................................................... 30 
5.1 Results of analysis of cell lines treated with both BMP4 and BMP7 ..................... 30 
5.1.1 Heat map .......................................................................................................... 30 
5.1.2 GO analysis ...................................................................................................... 31 
5.1.3 Transcription Factor analysis ........................................................................... 33 
5.1.4 KEGG pathway analysis .................................................................................. 34 
 
 
vii 
 
5.2 Results of analysis of cell lines treated only with BMP4 ....................................... 35 
5.2.1 Heat map .......................................................................................................... 35 
5.2.2 GO analysis ...................................................................................................... 37 
5.2.3 Transcription Factor analysis ........................................................................... 38 
5.2.4 KEGG pathway analysis .................................................................................. 39 
5.3 Group C genes analysis .......................................................................................... 41 
5.3.1 GO analysis ...................................................................................................... 41 
5.3.2 Transcription Factor analysis ........................................................................... 42 
5.3.3 KEGG pathway analysis .................................................................................. 43 
6. DISCUSSION .............................................................................................................. 44 
6.1 Analysis of cell lines treated with both BMP4 and BMP7 ..................................... 44 
6.2 Analysis of cell lines treated only with BMP4 ....................................................... 44 
6.3 Analysis of group C genes ...................................................................................... 46 
7. CONCLUSION ............................................................................................................ 47 
8. REFERENCES ............................................................................................................. 48 
9. APPENDICES .............................................................................................................. 56 
9.1 Analysis of cell lines treated with both BMP4 and BMP7 ..................................... 56 
9.1.1 Tables showing results of GO analysis ............................................................ 56 
9.1.2 Tables showing results of Transcription Factor analysis ................................. 58 
9.1.3 Tables showing results of KEGG pathway analysis ........................................ 61 
9.2 Analysis of cell lines treated only with BMP4 ....................................................... 64 
9.2.1 Tables showing results of GO analysis ............................................................ 64 
9.2.2 Tables showing results of Transcription Factor analysis ................................. 66 
9.2.3 Tables showing results of KEGG pathway analysis ........................................ 69 
9.3 Analysis of group C genes ...................................................................................... 71 
9.3.1 Tables showing results of GO analysis ............................................................ 71 
9.3.2 Tables showing results of Transcription Factor analysis ................................. 73 
9.3.3 Tables showing results of KEGG pathway analysis ........................................ 75 
 
 
 
viii 
 
ABBREVIATIONS 
AnnotationDbi  Annotation Database Interface 
BMP    Bone Morphogenetic Protein 
BMP4    Bone Morphogenetic Protein 4 
BMP7    Bone Morphogenetic Protein 7 
BMPR    Bone Morphogenetic Protein Receptor 
BRCA1   BReast CAncer gene one 
BRCA2   BReast CAncer gene two 
EST    Expressed Sequence Tag 
ER    Estrogen Receptor 
DEG    Differentially Expressed Genes 
DEP    Differentially Expressed Probes 
DNA     Deoxyribo Nucleic Acid 
DCIS     Ductal Carcinoma In Situ  
FISH    Fluorescence In Situ Hybridization   
GEO                          Gene Expression Omnibus 
GEP    Gene Expression Profiling 
GF    Growth Factor 
GH    Growth Hormone 
GO    Gene Ontology 
h    hour 
IGF    Insulin-like Growth Factor 
KEGG    Kyoto Encyclopedia of Genes and Genomes 
ix 
 
LCIS    Lobular Carcinoma In Situ  
Limma    Linear Models for Microarray Data 
MAPK    Mitogen Activated Protein Kinases 
MPSS    Massively Parallel Signature Sequencing 
mRNA    Messenger RNA 
RNA                              Ribo Nucleic Acid 
SMAD Homologue of Drosophila Mothers Against 
Decapentaplegic 
SNP    Single Nucleotide Polymorphism 
TGF - β   Transforming Growth Factor - β  
WebGestalt     WEB-based GEne SeT AnaLysis Toolkit  
 
 
 
 
 
 
 
 
 
 
1 
 
1. INTRODUCTION 
Bone morphogenetic proteins (BMP) are a family of ligands that belong to the 
transforming growth factor β (TGFβ) superfamily. BMPs have the ability to induce 
endochondral bone formation and regulation of transcription of target genes.  BMPs 
interact with specific receptors on the cell surface, referred to as Bone morphogenetic 
protein receptors (BMPRs). Phosphorylation of downstream targets is mediated by signal 
transduction through BMPs. There are many BMPs like BMP 1, 2, 3, 4, 5, 6, 7, 8a, 8b, 
10 and 15 with unique functions. In humans there are 21 members of BMP families. 
These regulate the transcription of target genes by signaling through type I and type II 
transmembrane serine-threonine receptors.  BMP4 is essential for muscle development, 
bone mineralization and ureteric bud development. BMP7 or osteogenic protein-1 plays 
a vital role in transformation of mesenchymal cells in to bone and cartilage (Table 1.1).  
The BMP signaling pathways regulates gene transcription. These pathways are initiated 
by the formation of heterotetramer. The BMP dimer binds to its type II receptor that 
recruits type I receptors resulting in the formation of heterotetramer with two receptors 
of each type. The type I receptor is phosphorylated by type II receptor. The SMAD 
cascade is one among the two pathways and the other pathway MAPK involves two 
mitogen activated protein kinase cascades. 
TGF-β family receptors use the SMAD signaling pathway to transduce signals. The type 
I receptor is phosphorylated by type II receptor. Phosphorylation of R-SMAD 1, 5 and 8 
takes place and the R-SMAD complex moves to nucleus. The downstream effect of R-
SMADs is prevented by dorsomorphin. 
BMP signaling is involved in tumor suppression, bone homeostasis, angiogenesis and 
metastasis. Among all the BMPs the BMP4 and BMP7 are known for their aberrant 
expression in primary breast cancer and bone metastases. The BMP4 and BMP7 treated 
cell lines reveal much information like cell proliferation and differentiation. Dealing with 
expression data determines differentially expressed genes and the transcriptional 
responses to the BMP4 and BMP7 signaling. BMP4 and BMP7 have been studied 
extensively in cancer biology to understand their role in metastasis and especially in 
breast cancer their role receives much attention from researchers. 
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Table 1.1 Information on BMP4 and BMP7 
Protein Name Gene 
Name 
Chromosome 
and location 
Protein 
family 
Functions 
 
BMP4 
 
Bone morphogenetic 
protein 4 
 
BMP4 
 
14q22-q23 
 
TGF-beta 
family 
Bone,  
cartilage 
development 
 
BMP7 
 
Bone morphogenetic 
protein 7 
 
BMP7 
 
20q13 
 
TGF-beta 
family 
 
Bone 
homeostasis 
 
BMP4 has been identified as breast cancer metastasis suppressor gene. The 4T1 
preclinical mammary mouse models had shown differences in the levels of BMP4 and 
coupled with highly metastatic or non-metastatic cells. Further studies indicated that the 
highly metastatic T1.2 mammary tumor cells express lower levels of BMP4 whereas the 
weakly or non-metastatic cells had higher levels of BMP4. Prevention of secondary 
tumor formation occurs as the 4T1.2 tumor cells become more susceptible to anoikis due 
the presence of BMP4 and prolongs the life of 4T1.2 tumor bearing mice. It is found that 
BMP4 act on both tumor cells and stromal components and suppresses metastasis. 
Further investigation was carried out on transcriptional alterations triggered by BMP4 
using microarray gene expression profiling. From 4T1.2, primary tumor cells were 
isolated and subjected to gene expression profiling. Ontology analysis of differentially 
expressed genes (DEG) revealed many pathways and target factors that affect breast 
cancer metastasis (Cao, 2011). 
The effect on global gene transcription in BMP4 and BMP7 treated breast cancer cell 
lines showed different expressions. As a response to these ligands the cellular functions, 
regulation of gene expression and signal transduction showed notable changes in the 
metabolism and cell proliferation. A set of genes expressed common molecular 
responses to BMP4 and BMP7 and were known as synexpression group of genes. This 
group of genes was obtained after several types of filtration (Rodriguez-Martinez et al., 
2011). 
Microarrays help researchers to study thousands of gene expression simultaneously. The 
role of microarray in breast cancer studies in inevitable. Both DNA and RNA 
microarrays play a major role in gene expression studies. There are about 1.5 million 
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cases of breast cancer worldwide according to Breast Cancer Statistics. The occurrence, 
proliferation and cure can only be understood when large number of genes is studied and 
such a massive exploration can be easily handled with microarray technology. Gene 
expression profiling is a method of measuring the expression of thousands of genes at 
once. The gene expression values are later analyzed using one of the software called 
Bioconductor. This software can be used for pre-processing, quality assessment, 
differential expression, clustering, classification, gene set enrichment analysis and 
genetical genomics. 
The aim of this thesis work was exploring the set of significant genes that respond to 
BMP4 and BMP7 by using the Bioconductor package and subject those genes to Gene 
Ontology, Transcription Factor and KEGG pathway analyses. This work was based on 
data provided by Rodriguez-Martinez from Laboratory of Cancer Genetics, Institute of 
Biomedical Technology, Finland. Finding out the significant genes would help in 
understanding their interactions with ligand molecules and also it helps in knowing the 
metabolic processes. The synexpression group of genes was also subjected to Gene 
Ontology, Transcription Factor and KEGG pathway analyses in order to find out the 
functions of genes and their pathways. The work has also been done with an approach 
that it opens an arena for investigating the genes that are expressed in primary breast 
cancer samples with that of identified set of genes from the breast cancer cell lines and 
there by drawing a comparison between in vivo and in vitro behavior of these genes. 
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2. REVIEW OF LITERATURE  
2.1 Breast cancer – An overview 
2.1.1 Breast cancer and its types 
Breast cancer is a form of cancer which is caused in the tissues of breast that are the 
inner linings of the ducts and lobules. Cancer may occur from ducts namely ductal 
carcinoma or from lobule namely lobular carcinoma. Breast cancer is one of the major 
cause of death in females and also one of the most common invasive cancers (Alarmo et 
al., 2010, Dumitrescu et al., 2005, Mundy et al., 1997, Naber et al., 2012). There are 
about 1.15 million cases of breast cancer diagnosed all over the world every year. Thirty 
percent of all cancer in women occurs in breast (Park et al., 2009). Abnormalities at gene 
level are the major cause of breast cancer. BRCA1, BRCA2, p53, PTEN, ATM, NBS1, 
LKB1, AR, ATM, BARD1, BRIP1, CHEK2, DIRAS3, ERBB2, NBN, PALB2, RAD50 
and RAD51 when variation happen in these high penetration genes, breast cancer occurs 
(Table 2.1.3). Inheritance contributes to 5-10% of cancer cases (Rajnish et al., 2012). 
The forms of breast cancer are invasive and non-invasive. Invasive form spread from 
milk duct or lobules to other tissues in breast. Non-invasive does not spread to other 
tissues and it is also called as “in situ”. Ductal carcinoma in situ (DCIS) or intraductal 
carcinoma and lobular carcinoma in situ (LCIS) are two main types of cancer (Sotiriou et 
al., 2003). Among estrogen receptor (ER) positive and estrogen receptor negative breast 
cancers, the estrogen receptor negative has the highest risk. ER negative breast cancer 
cells can be further classiﬁed into Erbb2/Her2/Neu positive, basal cell like and normal 
breast‐like subtypes, with the basal cell like breast cancer having the worst prognosis and 
the normal breast‐like the best prognosis (Otsuka et al., 2009). ER negative breast cancer 
can be further classiﬁed into luminal 22 subtype A, B and C, with luminal C having the 
worst and luminal A having the best prognosis. Furthermore, the clinical outcome can be 
predicted based on a 70 gene signatures in the primary tumor. This led to the hypothesis 
that metastatic traits are already acquired during early tumor genesis (van’t Veer et al., 
2002, Sorlie et al., 2001, Weigelt et al., 2005, Perou et al., 2000, Honrado et al., 2006). 
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2.1.2 Epidemiology of breast cancer  
National Cancer Institute has estimated that 232,340 women will be diagnosed with and 
39,620 women will die of breast cancer in 2013 in United States (Howlader et al., 2013, 
Desai et al., 2002). Breast cancer contributes to 16% of all female cancer, 22.9% of 
invasive cancer and 5% of breast cancer in women under age of 40 years, stated the 
World Health Organization in the year 2009. American Cancer Society provided the 
percentage of survival after diagnosis of breast cancer as 89% after five years, 82% after 
ten years of diagnosis and only 77% after fifteen years of diagnosis. The incidence of 
breast cancer is high in well developed countries and comparatively less in developing or 
under developed countries. United States has the highest incidence rates of 128.9 per 
100,000 women. All these statistics indicate the growing risk of cancer and increasing 
rates of mortality. This is the very main reason for extensive research which is carried 
out in breast cancer in order to find the potential target.  
 Table 2.1.3 Genes associated with breast cancer (Source: OMIM) 
Gene Gene/Locus 
MIM number 
Location Phenotype 
RAD54L 603615 1p34.1 Breast cancer, invasive ductal 
CASP8 601763 2q33.1 Breast cancer, protection against 
BARD1 601593 2q35 Breast cancer, susceptibility 
PIK3CA 171834 3q26.32 Breast cancer, somatic 
HMMR 600936 5q34 Breast cancer, susceptibility  
NQO2 160998 6p25.2 Breast cancer susceptibility 
RB1CC1 606837 8q11.23 Breast cancer, somatic 
SLC22A1L 602631 11p15.4 Breast cancer, somatic 
TSG101 601387 11p15.1 Breast cancer, somatic 
ATM 607585 11q22.3 Breast cancer, susceptibility  
KRAS 190070 12p12.1 Breast cancer, somatic 
BRCA2 600185 13q13.1 Breast cancer, male, susceptibility  
XRCC3 600675 14q32.33 Breast cancer, susceptibility  
AKT1 164730 14q32.33 Breast cancer, somatic 
RAD51A 179617 15q15.1 Breast cancer, susceptibility  
PALB2 610355 16p12.2 Breast cancer, susceptibility  
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Gene Gene/Locus 
MIM number 
Location Phenotype 
CDH1 192090 16q22.1 Breast cancer, lobular 
PHB 176705 17q21.33 Breast cancer, susceptibility  
BRIP1 605882 17q23.2 Breast cancer, early-onset 
PPM1D 605100 17q23.2 Breast cancer 
CHEK2 604373 22q12.1 Breast cancer, susceptibility  
 
2.1.3 Genes associated with breast cancer 
The table (2.1.3) shows the different genes and their respective role in breast cancer. 
Studies indicate that the breast cancer gene one and breast cancer gene two (BRCA1&2) 
are associated with inherited cancer in most cases. The role of the BRCA genes is to 
repair cell damage and keep normal growing breast cells. But when these genes contain 
abnormalities or mutations that are passed from generation to generation, the genes don't 
function normally and breast cancer risk increases. 10% of all breast cancers or 1 out of 
every 10 cases has abnormal BRCA1 and BRCA2 genes. The abnormalities of BRCAs 
are not only the causative of breast cancer but there is single nucleotide polymorphism 
(SNP) that is also found to be linked to the cause of breast cancer. SNPs are mutations in 
small regions of chromosomes. It is also seen that women who are detected with this 
type of cancer have a family history of breast cancer or ovarian cancer or any other 
cancer there by showing the inheritance of abnormal BRCA genes (Bishop 1999, Ford et 
al., 1998, Risch et al., 2001).  
Other than BCRA, there are several genes associated to breast cancer like ATM that 
helps to repair damaged DNA. Inheriting two abnormal copies of ATM gene causes the 
disease ataxia-telangiectasia, a rare disease that affects brain development. Inheriting one 
abnormal ATM gene has been linked to an increased rate of breast cancer in some 
families because the abnormal gene stops the cells from repairing damaged DNA. This 
gene and genes other than BRCA has less risk of causing cancer. p53 or TP53 gene 
provides instructions to the body for making a protein that stops tumor growth (Table 
2.1.3). Inheriting an abnormal p53 gene causes Li-Fraumeni syndrome, a disorder that 
causes people to develop soft tissue cancers at a young age. People with this rare 
syndrome have a higher-than-average-risk of breast cancer and several other cancers 
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including leukemia, brain tumor and sarcomas (Annegien et al., 2000, Georgia et al., 
2001). 
The CHEK2 gene also provides instructions for making a protein that stops tumor 
growth. Li-Fraumeni syndrome can also be caused by an inherited abnormal CHEK2 
gene. Even when an abnormal CHEK2 gene doesn't cause Li-Fraumeni syndrome, it can 
double breast cancer risk. The PTEN gene helps to regulate cell growth. An abnormal 
PTEN gene causes Cowden syndrome, a rare disorder in which people have a higher risk 
of both benign (not cancer) and cancerous breast tumor, as well as growths in the 
digestive tract, thyroid, uterus and ovaries. The CDH1 gene makes a protein that helps 
cells to bind together to form tissue. An abnormal CDH1 gene causes a rare type of 
stomach cancer at an early age. Women with an abnormal CDH1 gene also have an 
increased risk of invasive lobular breast cancer. Usually ATM, BRCA1, BRCA2, TP53 
are the genes that are responsible for DNA damage recognition and repair pathways. 
Mutations in these genes increase the breast cancer rate from moderate to high. Another 
gene CHEK2 has also been reported which belongs to the same pathway causes cancer 
when deletion occurs in this gene but all these mutations do not contribute to a high 
incidence of cancer and only up to 2 – 5% which requires further studies to find out the 
real factors that cause mutation in these genes and there by leading to breast cancer 
(Caroline et al., 2007).  
Human Epidermal Growth Factor Receptor 2 (HER2) is another widely studied gene in 
breast cancer belonging to epidermal growth factor receptor family. Though, it does not 
belong to the transforming growth factor family it is studied for its essential part in breast 
cancer especially in pathogenesis and progression stages. This gene is also known as 
erbB2 or neu gene. It is found to be over expressed in about 30% breast cancers. The 
over expression or amplified presence of this gene in patients results in lower survival 
rates and make them more susceptible to other diseases (Tan et al., 2007). 
2.2 BMP and SMAD pathways 
Bone morphogenetic proteins are a family of ligands that belong to the transforming 
growth factor β (TGFβ) superfamily. BMPs have the ability to induce endochondral bone 
formation and regulation of transcription of target genes.  BMPs interact with specific 
receptors on the cell surface, referred to as bone morphogenetic protein receptors 
(BMPRs). Phosphorylation of downstream targets is mediated by signal transduction 
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through BMPs. There are several BMPs like BMP 1, 2, 3, 4, 5, 6, 7, 8a, 8b, 10 and 15 
with unique functions (Table 2.2). In humans there are 21 members of BMP families that 
are involved in bone formation and developmental processes. These regulate the 
transcription of target genes by signaling through type I and type II transmembrane 
serine-threonine receptors. BMPs are extracellular signaling molecules that are able to 
regulate various cellular functions, proliferation, differentiation, apoptosis and migration. 
BMPs have been studied in several cancers and aberrant expression patterns of BMPs 
have been reported (Alarmo et al., 2010, Herpin et al., 2007).  
Table 2.2 Types of BMPs, their functions and Gene locus: 
(Source: http://en.wikipedia.org/wiki/Bone_morphogenetic_protein) 
 
BMP 
                  
Functions 
      
Gene Locus 
 
BMP1 
BMP1 does not belong to the TGF-β family of 
proteins. It is a metalloprotease that acts 
on procollagen I, II and III. It is involved in cartilage 
development 
Chromosome: 8;  
Location: 8p21 
 
BMP2 
Acts as a disulphide-linked homodimer and induces 
bone and cartilage formation. It is a candidate as 
a retinoid mediator. Plays a key role in osteoblast 
differentiation 
Chromosome: 20; 
Location: 20p12 
 
BMP3 
 
Induces bone formation. 
Chromosome: 14; 
Location: 14p22 
 
BMP4 
Regulates the formation of teeth, limbs and bone 
from mesoderm. It also plays a role in fracture repair, 
epidermis formation, dorsal-ventral axis formation and 
ovarian follicle development. 
Chromosome: 14; 
Location:14q22-q23 
 
BMP5 
 
Performs functions in cartilage development. 
Chromosome: 6; 
Location: 6p12.1 
 
BMP6 
Plays a role in joint integrity in adults. Controls iron 
homeostasis via regulation of hepcidin. 
Chromosome: 6; 
Location: 6p12.1 
 
BMP8a 
 
Involved in bone and cartilage development. 
Chromosome: 1; 
Location: 1p35–p32 
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BMP 
 
Functions 
 
Gene Locus 
 
BMP8b 
 
Expressed in the hippocampus. 
Chromosome: 1;  
Location: 1p35–p32 
 
BMP10 
May play a role in the trabeculation of the 
embryonic heart. 
Chromosome: 2; Location: 
2p14 
 
BMP15  
May play a role in oocyte and follicular 
development. 
Chromosome: X; Location: 
Xp11.2 
 
2.2.1 BMP Signaling pathway 
The BMP signaling pathways regulate gene transcription. These pathways are initiated 
by the formation of heterotetramer. The BMP dimer binds to its type II receptor that 
recruits type I receptors resulting in the formation of heterotetramer with two receptors 
of each type. The type I receptor is phosphorylated by type II receptor. The SMAD 
cascade is one among the two pathways and the other pathway  MAPK involves two 
mitogen activated protein kinase cascades. TGF-β family receptors use 
the SMAD signaling pathway to transduce signals (Figure 2.2.1). Phosphorylation of the 
cytoplasmic signaling molecules SMAD2 and SMAD3 takes place for the TGF-β 
pathway. The type I receptor is phosphorylated by type II receptor. Phosphorylation of 
R-SMAD 1, 5 and 8 takes place and the R-SMAD complex moves to nucleus in case of 
BMP pathway (Beck et al.,  2006, Chen et al.,  2004, Ikushima et al.,  2010, Kitisin et 
al.,  2007, Horbelt et al.,  2012, Meulmeester et al.,  2011).  
The downstream effects of R-SMADs is prevented by dorsomorphin. The TGF – β and 
BMP signaling is highly regulated because of their important role in bone development 
and tissue homeostasis. Diverse biological effects are regulated by activated SMAD. 
They couple with transcription factors resulting in cell-state specific modulation of 
transcription.  DLX2, ID1, ID2, JUNB, SOX4, STAT1 are the BMP responsive genes. 
The activin and BMP pathways are themselves attenuated by MAPK signaling at a 
number of levels (Candia et al., 1997, de Gorter et al., 2010, Kowanetz et al., 2004, 
Montero et al., 2008). In certain contexts, TGF-β signaling can also affect SMAD-
independent pathways, including Erk, SAPK/JNK and p38 MAPK pathways. Activation 
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of SMAD-independent pathways through TGF-β signaling is also common (Verheyen et 
al., 2007).   
The intracellular BMP signaling has been many times found ambiguous whether it is a 
simple pathway or network. BMPs bind to specific serine/threonine kinase receptors, 
which transduce the signal to the nucleus through SMAD proteins. The BMP signaling is 
regulated by many factors at cytoplasmic, nucleic and cellular levels. The factors when 
identified revealed the principle behind diverse effects of BMP signaling. These factors 
are BMP inducible and they form negative feedback loop thus resulting in inhibition of 
BMP pathway. An interesting fact that was found out is that the members of BMP-
SMAD pathway interact with the members of other pathways and resulting in crosstalk 
(Von Bubnoff et al., 2001). 
The present approach of research on BMPs is finding the clinical interventions of these 
proteins. Besides, playing a role in embryonic development and cellular functions, 
recombinant BMPs find its application in several clinical interventions such as non-union 
features and spinal fusions. Few knock out mouse models were constructed and the role 
BMPs was studied. These mouse models having mutated BMPs showed differences in 
heart, bone and cartilage developments.  To know how BMP affects these developments, 
a tissue specific knock out must be studied (Chen et al., 2004, Xiao et al., 2007).   
The BMP signaling pathway is initiated by the BMP receptors at the plasma membrane 
forming the heterotetrameric complex of type II and type I receptors and these are 
signaled by the SMAD to the nucleus. RGM proteins serve as co-receptors for BMPs. By 
interaction with membrane anchoring proteins R-SMADs exist in the cytoplasm. When 
phosphorylation by type I receptors takes place R-SMADs form complexes with SMAD 
- 4 (Figure 2.2.1). Translocation takes place into the nucleus and regulates transcription 
of target genes through interaction with transcription factor DNA-binding proteins and 
transcriptional co-activators. The growth of sophisticated technologies help in a better 
way in exploring signaling mechanisms of BMPs. Chromatin immunoprecipitation on 
microarray (ChIP-chip) analysis is a powerful method for identification of binding sites 
of transcription factors. The studies about BMP receptor inhibitors serve as a good 
source in understanding the regulation of many diseases such as anemia (Kohai 
Miyazono et al., 2010, Schmierer et al., 2007). 
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Figure 2.2.1 BMP Signaling Pathway (source: http://www.humpath.com) 
2.3 Role of BMPs in breast cancer 
Bone morphogenetic proteins exhibit diversified roles in breast cancer and they are 
dependent on time, concentration and cell type.  The BMPs can serve as potential 
therapeutic agents because it shows differential patterns of expression in breast cancer. 
Immunohistochemical methods determine the location and distribution of BMPs. Few 
BMPs showed significant levels of expression namely BMP2 and BMP7 whereas few 
others showed inconsistent variation in transcript levels and they are BMP1, 3, 4 and 5. 
The BMPs and their role in breast cancer is still a mystery to many researchers for their 
unpredictable behavior in cancerous cells (Davies et al., 2008).  
Studies suggest that BMPs are involved in both cancer promotion and inhibition. This 
makes it vivid that further exploration of BMPs is essential to conclude their role in 
cancer. The BMPs are the ligand molecules that increase and decrease cancerous cell 
growth and migration (Alarmo et al., 2010). 
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The inhibitory effect of BMPs in breast cancer is of much interest. This effect was 
proven when tumorous cells were induced by estrogen. Human breast cancer MCF-7 
cells were found to express estrogen receptors α and β, BMP receptors and SMAD 
signaling molecules. MCF-7 cell proliferation was stimulated by estradiol and 
membrane-impermeable estradiol. Estradiol induced cell mitosis was suppressed by 
BMP 2, 4, 6 and 7. BMP2 and 4 decreased the expression more than the other BMPs. 
Estradiol induced differential modulation of expression in BMP receptor, thereby 
causing different BMP responses. BMP6 and 7 preferentially inhibited estradiol-induced 
p38 phosphorylation. The inhibitory effects of BMP6 and 7 on p38 signaling expression 
were functionally involved in the suppression of estrogen-induced mitosis of breast 
cancer cells (Otsuka et al., 2009). 
Comparison of two subsets of estrogen receptor positive breast cancers was carried out, 
in order to identify proteins involved in the progression of estrogen receptor positive 
breast cancers. These subsets differed in tumor grade, cytogenetic instability and tumor 
proliferation for their differential gene expression. The studies suggested that the bone 
morphogenetic protein receptor IB (BMPR-IB) plays a major role in the progression and 
dedifferentiation of breast cancer cells. In tumor, estrogen receptor expression indicates 
better tumor differentiation and clinical outcome in invasive breast cancer but there is 
also existence of estrogen receptor positive, poorly differentiated carcinomas showing 
poor clinical outcome (Mike Helms et al., 2005).  
Western blot analysis revealed that downstream signaling of this receptor is mainly 
mediated via phosphorylation of SMAD 1 in estrogen receptor positive breast cancer. 
Estrogen receptor positive and negative breast cancers showed BMPR-IB expression. 
But impact on tumor grade, proliferation and cytogenetic instability as parameters of 
tumor progression were demonstrated in estrogen receptor positive carcinomas. 
Significant anti-apoptotic activity complemented the pro-proliferative effect. This was 
indicated by XIAP and IAP-2 expression. The same effect was found in many of the 
BMPR related cancer. Activated BMP/SMAD pathway in breast cancer leads to 
progression and dedifferentiation in estrogen receptor positive breast cancer (Mike 
Helms et al., 2005). 
The evidence that BMP act as tumor suppressor can be found out from that it plays its 
role in tumorigenesis. BMPs are also known as growth stimulators and anti-proliferative 
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or anti-growth molecules. BMPs act as growth and proliferation inhibitor but they are 
also found to enhance the growth and proliferation of the tumorous cells. They behave 
differently in different cancer environments and their mechanism of action is also 
different at molecular level. Proliferation is inhibited by BMP2 and BMP5. They also 
modulate steroidogenesis. This was found in human adrenocortical tumor cells carried 
out as an in vitro study. BMP2 act as growth inhibitor by creating cell cycle arrest in the 
G1-phase mediated by p21/WAF1/CIP1. Pepsinogen II - a gene serves as differentiation 
marker of glandular cells of stomach, is activated by this activity of BMP2 and there by 
indicating its role in gastric cancer. BMP2 is found to have proliferative and apoptotic 
activity on cancerous cells (Wen et al., 2004). Furthermore, BMP2 was also reported for 
its repressing effect on inhibitory activity of TGF-β pathway and there by establishing 
less proliferative cells of breast cancer. Similar effects were reported on BMP7 and 
BMP6 (Du et al., 2008).  
Migration and invasion are found to be characteristic of BMPs. BMP7 was reported to 
have enhanced cell migration and invasion. This differs from cell line to cell line and 
from an environment to another. Increased suppression of growth rate, invasion and 
migration of cells were found to be the regulatory effects of BMP7. BMP6 also exhibit 
similar action during metastasis and angiogenesis processes (Masudha et al., 2003). 
BMPs effect was profoundly seen in prostate cancer. In prostate cancer cells BMP2, 4 
and 7 have seen to be having an effect.  BMP2 have been reported for its role in many 
types of cancer such as human pancreatic cancer, ovarian cancer, mesothelioma, 
mucinous adenocarcinoma and many more (Hatakeryama et al., 1993, Le Page et al., 
2006).  
2.4 Role of BMP4 and BMP7 in breast cancer 
The signal transduction pathway of BMP4 is closely associated with the transcriptional 
response of the target genes. BMP4 like every other TGF-β superfamily member binds to 
BMPR 1 and BMPR 2 (Figure 2.4.1). This binding is followed by signal transduction. 
This signal transduction can take place by SMAD pathway or MAPK pathway but both 
resulting in the transcription of the target genes of BMP4 represented in figure 2.4.1. At 
certain circumstances, transcription is affected by downstream signaling with in the cell 
and this is due to transphosphorylation of BMPR1 by BMPR2 (Miyazono et al., 2010). 
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BMP4 belongs to the TGF-β superfamily. BMP4 plays its role in various types of cancer 
like breast cancer, brain cancer, bladder cancer and colorectal cancer. Breast cancer and 
effects of BMP4 is widely studied and such studies indicate that its expression is more in 
primary breast cancer tumor and cell lines. 
 
Figure 2.4.1 Signal Transduction Pathway of BMP4 
(source: http://en.wikipedia.org/wiki/File:BMP4_Signal_Transduction_Pathways.gif) 
The BMP4 effect was found in many types of breast cancers like node negative and 
steroid receptor positive. A series of findings had been reported on breast cancer and 
BMP4. In the year 2007 Montesano et al., reported that in mammary epithelial cells 
invasive growth is promoted by exogenous treatment of BMP4. BMP4 was found 
capable of inducing growth factor that results in proliferation as the cells get induced. 
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From many findings it was found that the real role of BMP4 remains critical yet 
unknown.  
Ketolainen et al., 2010, had shown G1 cell cycle arrest leading to suppression of growth 
upon BMP4 treatment in nine different cell lines. The decrease in the metastatic activity 
in a cell line was reported by Shon et al., 2009. Another exploratory work was carried 
out by Rodriguez-Martinez et al., 2011 was an approach that revealed BMP4 and 
BMP7’s transcriptional responses in breast cancer cell lines. The work involved seven 
breast cancer cell lines that were treated both with BMP4 and BMP7 and also three of 
the cell lines were treated with both of the ligands and the treatment was carried out on 
different hours of incubation from 30 minutes to 24 hours with an increase of hours as a 
time series experiment. The experiment was performed in a RNA microarray using 
Agilent whole human genome oligo array. The results were subjected to several types of 
filtration such as cell line specific, time point specific and general filtration. These 
filtrations were done in order to find out the differentially expressed genes.  
The transcriptional response to BMP4 and BMP7 were stated as more number of 
differentially expressed genes was found in BMP4 treated than in BMP7 treated cell 
lines. But there may be a conclusion that it is true in all cases because the cell line that 
were treated with both BMP4 and BMP7 did not show any such results and further 
another analyses was made in order to find out the time point specific effect on the 
response of the genes. Temporal variation was noticed when these time point specific 
observations were made. Temporal variation is the pattern shown by gene clusters in 
such a way that they remain up regulated in some cell lines and down regulated in some 
cell lines. Later upon general filtering of the expression data, more pronounced effect of 
BMP4 was observed than BMP7 on gene transcription. Another unique outcome of this 
work was synexpression group of genes that is these genes show similar expression 
either up regulated or down regulated simultaneously. They also contain common cis and 
trans acting elements. There were 210 such probes resulting in 154 annotated genes. The 
genes were found to be involved in development and morphogenesis when they were 
subjected to GO analysis (Rodriguez-Martinez et al., 2011).  
Though BMP7 has been reported for its potential role in inhibiting cell proliferation in 
many forms of cancer like prostate, thyroid and colorectal cancer but its role in breast 
cancer is still under experimentation. Studies indicate that elevated levels of BMP7 in 
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breast tumor tissues when compared with normal mammary gland tissue. The expression 
of BMP7 in primary tumor has been extensively reported (Alarmo et al., 2009).  BMP7 
is referred to as pleiotropic signaling molecule. Unlike other TGF-β family members, 
BMP7 reduces the bone metastasis formation and growth in tumorous cells by making 
their association in the early stages of bone metastasis. This work made a different 
approach to study the breast cancer cell phenotype regulated by BMP7. Among the cell 
lines chosen for the study, few cell lines were BMP7 silenced and few were added with 
BMP7.  
The phenotype of each cell line was observed. The changes in growth of the BMP7 
silenced cells were due to the mechanisms of BMP7 like G1 cell cycle arrest and resulted 
in inhibition of growth. On the other hand, the cells treated with BMP7 showed no 
apoptosis. There were significant changes in the cell migration, cell invasion and growth 
all being influenced by BMP7.  
So far in prostate cancer, myeloma and anaplastic thyroid carcinoma addition of BMP7 
was observed to reduce proliferation further enunciated by decreased tumor growth in 
mouse xenograft. The BMP7 phosphorylates the SMAD1/5/8 and there by BMP 
signaling pathway takes place in both types of cell lines that exhibited cell growth or cell 
inhibition. This proves that the SMAD 4 mutations are unlikely to happen in breast 
cancer cells and it was also expressed in different levels. It can be said that there are 
multiple factors that influence the BMP7 functioning (Alarmo et al., 2009). 
The study carried out with breast tumor cell lines and breast tumor tissue samples reveal 
that the expression was not uniform for all cell lines but were cell line specific. Few cell 
lines showed BMP7 expression at mRNA level. BMP7 expression was not enhanced by 
the epidermal growth factor (EGF). Usually EGF enhances the expression of BMPs as 
they are dependent on EGF for regulation and this kindles further interest in the 
behaviour of BMP7. BMP6 another family member of BMP was enhanced by EGF 
makes it a very intriguing mechanism. All these studies showed that BMP7 undergoes a 
unique expression level in different samples and under different conditions. There were 
no incidences of similar expression among uniformly treated cell lines. Either cell 
proliferation or cell cycle arrest was observed (Schwalbe et al., 2003).  
Overexpressed BMP7 in primary breast cancer was reported in a study carried out by 
(Alarmo et al., 2006). In twenty two cell lines and in about hundred and forty six primary 
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breast tumor samples the gene copy number and expression of BMP7 was observed. In 
16% of primary tumor cases, the gene copy number was increased. With the help of 
fluorescence in situ hybridization technique (FISH) variations in gene copy numbers of 
BMP7 in each cell line was determined. The increase in gene copy number does not 
greatly influence the mRNA levels in either cell lines or tissue samples. The alterations 
in the levels of BMP7 remain one of the reasons for the overexpression of BMP7 protein 
and also for the development of breast cancer apart from being playing an important role 
in vertebrate bone development. 
2.5 DNA and RNA Microarrays and its applications in Gene Expression 
Profiling 
Microarray technology employs a two dimensional array on a solid surface such as glass 
or silicon thin film which is used to assay higher quantity of biological samples. It was 
first invented by Patrick Brown in 1995. DNA and RNA microarrays are those that 
replaced the traditional biological assays. DNA microarrays have been used for many 
experiments that involve gene expression studies that measures DNA and RNA 
microarrays for studying thousands of messenger RNA (mRNA) transcripts. These serve 
as an invincible tool to study thousands of genes simultaneously and often referred to as 
a high-capacity system that takes few microliters of sample to determine several number 
of genes (Adi et al., 2006, Stuart et al., 2001, Ziv Bar 2004). Microarrays can be 
classified based on length of probes, manufacturing method and number of samples that 
can be profiled on to the array simultaneously. 
Affymetrix, Agilent, Illumina and Nimblegen are the manufacturers of different kinds of 
arrays. The largest number of probes is found in complementary DNA array (cDNA) and 
lowest number of probes is found in oligonucleotide arrays. Here, probe stands for the 
nucleotide surface that is attached to the surface of the slide. The manufacturing methods 
also differ from array to array. Usually, cDNA arrays are manufactured using deposition, 
while oligonucleotide arrays are manufactured using in-situ technologies. There are three 
different types of in-situ technologies photolithography, ink-jet printing and 
electrochemical synthesis. The type of array used determines the type of experiment 
carried out. There are many types of array experiments such as Gene Expression 
Profiling, Single Nucleotide Polymorphisms detection, Tiling Array, Comparative 
Genomic Hybridization and many more (Maynard et al.,  2003, Romero et al.,  2002, 
Weinheim 2003) .  
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All these experiment types are useful in research and find its application in many ways 
such as the diagnosis and prognosis of hereditary diseases by detecting deletions and 
other mutations in genes. Single-channel arrays analyze a single sample at a time 
whereas multiple-channel arrays can analyze two or more samples simultaneously. Time 
series experiments using microarrays are challenging experiments where samples under 
different treatment and different conditions are studied and hence multiple channel arrays 
are used (Houts 2000). There are also growing need for algorithms in order to analyze 
these time series experiments (Schena 2000, Spellman et al, 1998, Friedman et al., 
2000). 
In medicine exploring gene transcriptional responses and conditions to specific target, 
environment and drug is very essential to understand the mechanism of the disease and 
to develop therapies. Diseases that are not well characterized because of the lack of 
information on cellular, molecular and genetic mechanisms are answered easily using 
microarrays (Knudsen 2004, Leppert et al, 2006, Muhle et al., 2001). The role of 
microarray is found very useful in complete cycle of disease mechanism such as 
identifying diagnostic or prognostic biomarkers, classifying diseases like tumors with 
different prognosis that are in differentiable by microscopic examination, monitoring the 
response to therapy and understanding the mechanisms involved in the genesis of disease 
processes. 
The applications of microarray in various fields of biological science is fast growing and 
limitless. The following are few applications of it in scientific research:  
Cancer research finds its easiest way out to study cancerous samples using microarray 
technology. In a research study conducted by (Grigoriadis et al.,  2006), a comparative 
study was done by isolating malignant neoplastic epithelial cells from primary breast 
cancers, luminal and myoepithelial cells isolated from normal human breast tissue by 
immunomagnetic separation methods. Massively parallel signature sequencing (MPSS) 
and four different genome wide microarray platforms were used for this expression 
profiling. 
6,553 differentially expressed genes were identified by MPSS method. Microarray 
profiling of primary tumor epithelial cells and 90% of normal luminal cells was carried 
out. Using microarray technology significant expression level changes between these two 
samples were detected and 4,149 transcripts were found out. There were 8,051 genes that 
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resulted in a combined differential tumor epithelial transcriptome. A list of 907 and 955 
transcripts whose expression differed between luminal epithelial cells and myoepithelial 
cells were identified by microarray gene signatures. As a result of these findings, genes 
that encode for periostin were found out. In this way the molecular changes in malignant 
epithelial cells in breast cancers were studied using microarray. 
Whole genome sequencing is another fascinating field of research made easy with the 
application of microarray. The whole genome of several organisms are sequenced by 
sequencing methods and differentially expressed genes are found out using arrays. 
Studies carried out by (Kristen et al., 2006) involved whole genome sequencing. Growth 
Hormone (GH) is important in the development and maintenance of bone. The molecular 
pathways such as insulin-like growth factors (IGF) still remain to be studied in detail to 
understand its association with GH in a wider way. This experiment showed the GH 
signaling pathway using mice which was deficient of GH and later was injected with it to 
study the differences in the pathways.  
The microarray analysis of the RNA samples showed important aspects such as 
differential expression of six thousand one hundred and sixty genes followed by higher 
number genes that were up regulated after injection of growth hormone. The study was 
also able to characterize the genes as expressed sequence tags (EST) and many genes 
were categorized under Gene Ontology. On the microarray, nineteen thousand and eighty 
one genes were found to an intensity of greater than hundred and there were three 
hundred and ninety five genes that were categorized under forty nine GO categories 
(Kristen et al., 2006).  
Though the IGF independent and dependent pathways by which growth hormone acts in 
bone still remains unrevealed, with the help of microarray several genes that are 
associated with common signaling pathways were revealed on whole genome had been a 
notable contribution. These types of experiments greatly reveal information on 
associated genes and sequencing of those genes may help in finding out different forms 
of genetic abnormalities, percentage of inheritance of those abnormalities to the progeny 
and also causatives of such abnormalities as in most cases the carcinogens. 
Breast cancer research and its importance had been already discussed in the previous 
parts and here the role of microarray in experiments to understand the multiple molecular 
interactions associated with breast cancer is being discussed. An excellent, integrated, 
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approach towards understanding the multiple molecular events and mechanisms by 
which cancer may develop can be studied with the application of gene expression 
profiling using microarray. Cellular pathways such as cellular pathways including cell 
cycle, growth, survival and apoptosis are disrupted by the process of oncogenesis. A 
snapshot of the complete cellular transcriptome on a single microarray chip provided by 
the microarray hybridization helps the researchers to find out the complex interactions of 
genes (Plamena et al., 2010).  
Changes in gene expression of epithelial and stromal cells occur during progression of 
cancer.  The stromal cells exhibit extensive gene expression and these were studied using 
expression profiling. Fourteen patients with primary ductal breast cancer were chosen 
and 78.6% were ER positive and 78.6% were lymph node positive. They all belonged to 
premenopausal group and their stromal and epithelial tumor cells were studied for 
expression under different stages of tumor progression (Xiao et al., 2009, de visser et al., 
2006, Clement et al., 2008, Strausberg et al., 2005).  
This exploratory analysis of microenvironment in breast cancer is very limited till date. 
These findings reveal that the tumor associated stromal cells expression is influenced by 
the components of the extracellular matrix and the extracellular matrix remodeling 
matrix metalloproteases. The interactions between tumor cells and the various immune 
cells are complex however, ranging from tumor growth-suppressing effects to tumor 
growth-promoting effects (Xiao et al., 2009, de visser et al., 2006, Clement et al., 2008, 
Strausberg et al., 2005). 
Several specific gene alterations have been implicated in breast cancer progression. 
Evaluation of global gene expression patterns using microarray technology helps in 
understanding the molecular basis of the disease. Gene expression in four different breast 
cancer cell lines T47D, MDA231, SKBR3 and BT474 were studied using cDNA 
microarrays containing 1,700 and 19,000 sequence-verified human cDNAs (Nalan et al., 
2001).   
Each hybridization was compared between Cy5-labeled complementary DNA from one 
of the cell lines with Cy3-labeled cDNA from a reference sample. This work aimed at 
finding out the consistency and reproducibility of the technology and for that purpose 
subsequent hybridization with reciprocal labeling was carried out. With this method, a 
system was developed for analysis of breast cancer samples and also to determine genes 
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that have common pathways that are also involved in breast carcinogenesis (Nalan et al., 
2001).  
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3. OBJECTIVES 
1. Detection of target genes of BMP4 and BMP7 ligands from top most regulated 
genes upon BMP4 and BMP7 treatment of the breast cancer cell lines. 
2. Detection of BMP4 target genes from list of top most regulated genes upon 
BMP4 treatment of the breast cancer cell lines.  
3. Analysis of Gene Ontology, Transcription Factor Target (Enrichment Analysis) 
and KEGG pathway of genes from cell line samples treated with BMP4 and 
BMP7 and those treated only with BMP4 using WEB-based GEne SeT AnaLysis 
Toolkit (WebGestalt) tool. 
4. Analysis of Gene Ontology, Transcription Factor Target (Enrichment Analysis) 
and KEGG pathway of group C genes that resulted from hierarchical clustering.  
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4. MATERIALS AND METHODS 
4.1 MATERIALS  
4.1.1 Microarray data 
The microarray data was downloaded from gene expression omnibus (GEO) database 
using the accession number GSE31605. This microarray data was submitted by 
Rodriguez-Martinez, Laboratory of Cancer Genetics, Institute of Biomedical 
Technology, University of Tampere and Centre of Laboratory of Medicine, Tampere 
University Hospital, Finland. (Analysis of BMP4 and BMP7 signaling in breast cancer 
cells unveils time-dependent transcription patterns and highlights a common 
synexpression group of genes, Rodriguez-Martinez et al., BMC Medical Genomics 2011, 
4:80). This microarray data was used for the entire analysis of this work. 
The experiment carried out by Rodriguez-Martinez was expression profiling by array and 
the platform used was Agilent -014850 Whole Human Genome Oligo Microarray 4x44K 
G4112F. This experiment involved treatment of seven breast cancer cell lines namely 
HCC1954, MDA-MB-361, ZR-75-30, HCC1419, SK-BR-3, MDA-MB-231 and T-47D 
with recombinant human BMP4 and BMP7 proteins (ligands). The cell lines HCC1954, 
MDA-MB-361, ZR-75-30 were treated with both BMP4 and BMP7 separately while 
HCC1419, SK-BR-3 cell lines were treated only with BMP4. MDA-MB-231 and T-47D 
cell lines were treated with only BMP7 (Table 4.1.1). Total RNA from these cell lines 
were extracted at six different time points like 30min, 1h, 3h, 6h, 12h and 24h after the 
treatment with BMP4 and BMP7. Later, these RNA were labeled with Cy-5 and vehicle 
treated cells with Cy-3 for generating fluorescence and were hybridized to the 
microarray and resulting in a two-color data. The scanned microarray data had been 
submitted to GEO.  For this work, the cell lines treated with both BMP4 and BMP7 and 
also the cell lines treated with only BMP4 were chosen for analysis. The genes that 
respond to the signaling of the ligands were found out.  
Table 4.1.1: List of treatment of cell lines with BMP4 and BMP7 
Name of the cell line Name of the ligands used for treatment 
HCC1954 BMP4 and BMP7  
MDA-MB-361 BMP4 and BMP7  
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Name of the Cell line Name of the ligands used for treatment 
ZR-75-30 BMP4 and BMP7  
HCC1419 BMP4 
SK-BR-3 BMP4 
MDA-MB-231 BMP7 
T-47D BMP7 
 
4.1.2 Hierarchically clustered group C genes 
 A list containing expression values represented as log2 ratios was provided as an 
additional file from the Laboratory of Cancer Genetics, Institute of Biomedical 
Technology, University of Tampere and Centre of Laboratory of Medicine, Tampere 
University Hospital, Finland. The group C genes showed a common synexpression in 
response to BMP4 and BMP7 signaling and it had 210 probes. These set of genes 
revealed elements of similarity in transcriptional response to the BMP4 and BMP7 
treatment indicating that they share common signaling pathways of BMP4 and BMP7. 
The functions of these genes are regulation of gene expression and regulation of 
development and morphogenesis. Hence, was found interesting to explore further in this 
work.  
4.1.3 Tools used for analysis of Microarray data 
For the analysis of microarray data, Bioconductor version 2.12 package in R 
programming environment version 2.15.2 was used.  Bioconductor is an open source 
platform that serves to carry out pre-processing, quality assessment, differential 
expression, clustering and classification, gene set enrichment analysis and genetical 
genomics of data sets by developing various packages. It can be used on various 
platforms like Affymetrix, Illumina, Nimblegen and Agilent. Limma, a library of 
Bioconductor was used to analyze, construct linear models and to study differential 
expression of genes and also for producing heat maps. This library served as an 
inevitable tool for finding significant genes. Annotation Database Interface 
(AnnotationDbi) and Genomic Features are packages curated by Bioconductor were also 
used. AnnotationDbi provides user interface and database connection code for annotation 
data packages using SQLite data storage and required by annotations of all types. 
Genomic Feature exposes an annotation database generated from UCSC by exposing 
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these as FeatureDb objects. plyr is a package of tools for splitting, applying and 
combining data which was also used. gplots is a package for plotting data which was 
used to produce heat maps from the resulting significant genes after each analysis. 
4.1.4 WEB-based GEne SeT AnaLysis Toolkit 
This is an online tool with so many enrichment analysis options like Phenotype Analysis, 
Disease Association Analysis, Drug Association Analysis and Cytogenetic Band 
Analysis. To study the Gene Ontology, Transcription Factor Target (Enrichment 
Analysis) and KEGG pathway of genes WebGestalt was used and the above mentioned 
enrichment analyses were carried out in this work using gene lists. There are three 
different GO slim classification analysis provided by WebGestalt namely Biological 
process, Molecular function and Cellular component.  
4.2 METHODS 
In order to carry out various analyses the R programming environment was set up by 
downloading the R version 2.15.2 from http://cran.r-project.org/. The cran is the 
repository for the packages in R and the packages in Bioconductor can be downloaded 
from its own website. The Bioconductor packages were installed by typing the following 
commands in R window:  
source (http://bioconductor.org/biocLite.R)  
biocLite() 
Further, the packages GenomicFeatures and AnnotationDbi were installed by typing the 
following command in R window: 
biocLite(c("GenomicFeatures", "AnnotationDbi")) 
The package plyr was installed from the option ‘Install Package’ in R window and plyr 
was selected from the list. gplots was downloaded as zip file from (http://cran.r-
project.org/web/packages/gplots/index.html) and unzipped in R window. 
The microarray data series was obtained from GEO by browsing under the option 
‘Series’ using the accession number GSE31605 (http://www.ncbi.nlm.nih.gov/geo/). 
From the webpage, GSE31605_RAW.tar file was downloaded and the link is as follows 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31605). A tab delimited text 
file named as ‘Targets.txt’ was created which served as the target frame. This file contains 
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different columns such as FileName which gives the name of the image analysis output 
file, Name, CellType - name of the cell lines, Cy5 Cy3 - RNA type labelled with the dye, 
Time - 30mins, 1h, 3h, 6h, 12h and 24h. The target file needs to have the columns 
FileName, Cy3, Cy5 but other columns like time, date, replicates are optional. The 
purpose of this file is that it lists the RNA target hybridized to each channel of each array 
and has a row of information on each microarray in general.  
4.2.1 Analysis of cell lines treated with both BMP4 and BMP7 
The cell lines treated with both BMP4 and BMP7 were MBA-MB-361, HCC-1954, ZR-
75-30. Limma, plyr and gplots libraries were loaded in R for this analysis. At first, the 
‘Target.txt’ file was read in and followed by the data function of studying the foreground 
and background intensities of the images in to an RG list. RG is Red-Green list which is 
a data object and a class used to store raw two color intensities as they are read in from 
an image analysis output file and then it is read. Normalization is a preprocessing step 
used to correct the systematic difference between genes or arrays. This step is also 
known as background correction where subtraction of background intensity from the 
foreground intensity is carried out for each spot. There are two types of normalization 
namely within array and between array. For this step, between array normalization with 
Aquantile method was carried out and this method normalizes intensities or log-ratios to 
be comparable across arrays. The quantile normalization when applied to the A-values 
makes the distributions uniform across each array and each channel. Normalization is 
also a quality control measure for Agilent two color data. The density plots were also 
constructed. These were the preliminary steps involved in the analysis.  
As a next step, a model matrix was designed which describes the hybridization of RNA 
targets to the arrays in the experiment. Following the designing of a model matrix, a 
contrast matrix was built. The contrast matrix allows the coefficients defined by the 
design matrix to be combined into the contrasts of interest and specifies which 
comparison to be made between the RNA targets. In this step, it was analysis of both 
BMP4 and BMP7 RNA targets. In design matrix, each row corresponds to an array in the 
experiment and each column corresponds to a coefficient. The matrix which was 
constructed was used to fit a linear model. Emprical Bayes was the method used and it is 
one of the widely used methods in limma than other statistical methods like t - test, etc., 
it is the statistical approach with parameter inferred from the data. 
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The results after applying the empirical Bayes were stored in an object and top Table was 
saved. The top Table consisted of columns such as row numbers in the original data, 
logFC - log2 based fold change values, t- moderated t-statistics from the empirical Bayes 
method, P values, adj.P.value - p-values corrected for multiple comparisons using 
Benjamini & Hochberg’s false discovery rate, B - log odds of DEG. Based on the log FC 
values the regulation of genes were estimated. The negative log FC values indicated 
down regulation and positive log FC values indicated up regulation of genes. The 
obtained top Table was subjected to various filtrations like filtering out the probes with p 
- values less than 0.00, positive and negative control probes were removed. For 
construction of heat map another table was created from the top Table. This table had 
only those probes that occurred in common in all the three cell lines and their log FC 
values were added to the table and were used to produce a heat map in R.  In this way 
only significant probes that expressed in all the three cell lines were identified and their 
regulation was studied. 
4.2.2 Analysis of cell lines treated only with BMP4 
The cell lines treated only with BMP4 were alone chosen for this step. They were MBA-
MB-361, HCC-1954, ZR-75-30, HCC-1419 and SK-BR-30. The analysis steps were so 
close to the analysis of both BMP4 and BMP7 treated cell lines but when selecting the 
targets only BMP4 was selected for analysis. As a first step, the ‘Target.txt’ file was read 
and followed by the preliminary steps such as making RG list and normalization.  
The linear model was set after constructing the design matrix and contrast matrix. 
Empirical Bayes method was applied and a top Table was obtained with columns such as 
row numbers, log FC, t values, P - values, adj.P.values and B values. The top Table was 
then filtered out from positive and negative controls. Common genes present in all the 
five cell lines were chosen. These genes and their log FC values were made as a separate 
table and were used for construction of heat map and their regulation was studied. 
4.2.3 Gene Ontology, Transcription Factor, KEGG pathway analysis of cell lines 
treated with both BMP4 and BMP7 and only with BMP4 
The list of probes that were generated from above analysis 4.2.1 and 4.2.2 were made in 
to separate text files that contain only the probe Id’s column, as this web tool can process 
files in “.txt and .tsv” format. At first, the text file consisting of probe Ids of both BMP4 
and BMP7 was analyzed. The text file for BMP4 and BMP7 treated cell lines contained 
92 probes and the text file for BMP4 treated cell lines had 81 probes. The text files 
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served as target files for all the three analyses namely Gene Ontology, Transcription 
Factor and KEGG pathway. The following steps were performed for Gene Ontology 
analysis: 
 In the webpage of WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt/), the 
target text file was uploaded and Homo sapiens were selected as the organism of 
interest.  
 As a next step, Gene ID type was chosen. The list of genes that corresponds to 
the type of gene list that was uploaded had been selected and it was Agilent 
whole genome 4*44K_v1 of Homo sapiens for this analysis.  
 From the menu under the “Enrichment Analysis” - GO analysis was chosen and 
the analysis was carried out with following parameters such as reference set for 
enrichment analysis - hsapiens_Agilent_ Wholegenome_4*44k_v1. This 
parameter decides the reference set of genes to be compared with for statistical 
analysis in order to find out enriched gene sets. Hypergeometric statistical 
method was chosen as a default parameter for enrichment evaluation analysis. 
Multiple test adjustment was an essential parameter which adjusts the p value 
using Benjamini and Hochberg method.  
 Top 10 significant pathways were chosen by selecting the default parameter top 
10 for significance level. The final parameter was selecting a minimum number 
of genes from the uploaded file that serves as most interesting genes in a pathway 
and so that the pathway can be considered. It was set as two in order to get those 
pathways that had minimum of two significant genes involved in it from the 
uploaded file.  
The result was obtained as separate file and was downloaded. The same procedure was 
followed for Transcription Factor analysis and KEGG pathway analysis but with a 
change in the step where under ‘Enrichment Analysis’ - Transcription Factor and KEGG 
pathway were chosen for each analysis respectively among many other analysis that 
were listed. For all the analyses the parameters remained the same as above. For GO, 
Transcription Factor and KEGG pathway analyses of only BMP4 treated cell lines, the 
probe Ids were extracted and made into a target text file and the other steps were carried 
out in the same way as it was carried out for both BMP4 and BMP7 treated cell lines 
using WebGestalt. The result files were downloaded and saved. 
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4.2.4 Gene Ontology, Transcription Factor, KEGG pathway analysis of group C 
genes 
List of probe Ids of group C genes from excel file were extracted and made in to a text 
file that contains only the probe Id’s column, as this web tool can process files in “.txt 
and .tsv” format. It contained 210 probes in total. This text file served as target file for all 
the three analyses namely Gene Ontology, Transcription Factor and KEGG pathway. The 
following steps were performed for Gene Ontology analysis.  
 In the webpage of WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt/), the 
target text file was uploaded and Homo sapiens were selected as the organism of 
interest.  
 As a next step, Gene ID type was chosen. The list of genes that corresponds to 
the type of gene list that was uploaded had been selected and it was Agilent 
whole genome 4*44K_v1 of Homo sapiens for this analysis.  
 From the menu under the “Enrichment Analysis” – GO analysis was chosen and 
the analysis was carried out with following parameters such as reference set for 
enrichment analysis - hsapiens_Agilent_ Wholegenome_4*44k_v1. This 
parameter decides the reference set of genes to be compared with for statistical 
analysis in order to find out enriched gene sets. Hypergeometric statistical 
method was chosen as a default parameter for enrichment evaluation analysis. 
Multiple test adjustment was an essential parameter which adjusts the p value 
using Benjamini and Hochberg method.  
 Top 10 significant pathways were chosen by selecting the default parameter top 
10 for significance level. The final parameter was selecting a minimum number 
of genes from the uploaded file that serves as most interesting genes in a pathway 
and so that the pathway can be considered. It was set as two in order to get those 
pathways that had minimum of two significant genes involved in it from the 
uploaded file.  
The result was obtained as separate file and was downloaded. The same procedure was 
followed for Transcription Factor Analysis and KEGG pathway analysis but with a 
change in the step where under ‘Enrichment Analysis’ – Transcription Factor and KEGG 
pathway were chosen for each analysis respectively. For all the analyses the parameters 
remained the same and result files were saved. 
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5. RESULTS 
5.1 Results of analysis of cell lines treated with both BMP4 and BMP7 
5.1.1 Heat map 
Heat map was constructed in order to find out the up and down regulated genes using the 
list of genes from the top Table. Figure 5.1.1 shows about ninety three probes that codes 
for different genes and their log FC values plotted against each other for each line. From 
the heat map it was seen that the genes followed different patterns of expression in each 
cell line.  
 
Figure 5.1.1 Heat map showing over expressed and under expressed genes 
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Heat map showing over expressed and under expressed genes of cell lines HCC_1954, 
MDA_MB_361 and ZR_75_30 treated with BMP4 and BMP7. In the heat map, each 
row represents a gene, represented by its probe ID and the columns represent respective 
cell lines. The log FC values of each gene in each cell line was plotted in order to read 
the expression of genes. The heat map showing, up regulated genes in red and down 
expressed genes in green and was identified as indicating different levels of expression 
of same gene but differing from cell line to cell line (Figure 5.1.1). 
The red color indicates over expressed or up regulated genes while green color indicates 
under expressed or down regulated genes. There were twenty genes that under expressed 
in cell line ZR_75_30 but the same set of genes were over expressed in cell lines 
HCC_1954 and MDA_MB_361. Further, it was also seen that the heat map showing 
another set of twenty one genes which were under expressed in MDA_MB_361 cell line 
but over expressed in HCC_1954 and ZR_75_30. In ZR_75_30 and MDA_MB_361 nine 
genes were found to under express and in HCC_1954 they had remained showing over 
expression. The set of genes were also found to have biological functions when they 
were subjected to GO analysis. 
5.1.2 GO analysis 
Among 92 probe Ids that were uploaded, 42 probes were mapped to Entrez Ids. The GO 
analysis provided enriched GO categories under Biological processes, Molecular 
function and Cellular component. The following table (5.1.2 a & b) shows the set of 
genes and their biological functions. The genes were grouped under one biological 
process based on the values such as number of reference genes in the category (C), 
number of genes in the gene set and also in the category (O), expected number in the 
category (E), Ratio of enrichment (R), p value from hypergeometric test (rawP) and p 
value adjusted by multiple test adjustment (adjP). Similarly the tables were obtained for 
set of genes for molecular functions and cellular components. Here, genes involved in 
positive regulation of isotype switching to IgG isotypes and peptidyl-tyrosine 
phosphorylation are shown. There are four genes playing a role in positive regulation of 
isotype switching to IgG isotypes and five genes taking part in peptidyl-tyrosine 
phosphorylation. The genes were grouped based on the p value (Table 5.1.2 a & b). 
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Table 5.1.2 (a) Biological processes of GO analysis 
GO  Biological Process C   O  E R rawP adjP           
004830
4 
positive regulation of isotype 
switching to IgG isotypes 
7 4 0.01 269.68 5.75e-10 3.97 
e-0 
User Id Value Entrez ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P125451 NA 5788 ENSG00000081237 PTPRC 
protein tyrosine 
phosphatase, 
receptor type, C 
A_23_P57036 NA 958 ENSG00000101017 CD40 
CD40 molecule, 
TNF receptor 
superfamily 
member 5 
A_23_P30122 NA 3558 ENSG00000109471 IL2 interleukin 2 
A_23_P213706 NA 3565 ENSG00000113520 IL4 interleukin 4 
 
Table 5.1.2 (b)  
GO  Biological Process C   O  E R rawP adjP           
0018108 peptidyl-tyrosine 
phosphorylation 
201 8 0.43 18.78 6.64e-09 9.29e-
07 
 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P125451 NA 5788 ENSG00000081237 PTPRC 
protein 
tyrosine 
phosphatase, 
receptor type, 
C 
A_23_P93787 NA 3082 ENSG00000019991 HGF 
hepatocyte 
growth factor 
(hepapoietin 
A; scatter 
factor) 
A_24_P397817 NA 3952 ENSG00000174697 LEP leptin 
A_23_P57036 NA 958 ENSG00000101017 CD40 
CD40 
molecule, TNF 
receptor 
superfamily 
member 5 
A_23_P110253 NA 3815 ENSG00000157404 KIT 
v-kit Hardy-
Zuckerman 4 
feline sarcoma 
viral oncogene 
homolog 
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5.1.3 Transcription Factor analysis 
Among 92 probes that were uploaded, 42 probes were mapped to Entrez Ids. The table 
(5.1.3 a & b) shows some of the significantly enriched gene sets. The Entrez genes were 
represented by Entrez Ids and the description defines about the gene. The following 
defines each of the category by which the set of genes were categorized - number of 
reference genes in the category (C), number of genes in the gene set and also in the 
category (O), expected number in the category (E), Ratio of enrichment (R), p value 
from hypergeometric test (rawP) and p value adjusted by multiple test adjustment (Table 
5.1.3 a & b). 
Table 5.1.3 (a) Transcription Target: hsa_TGCTGAY_UNKNOWN DB_ID:2367 
C=530; O=6; E=0.52; R=11.62; rawP=1.21e-05; adjP=0.0012 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_24_P335781 NA 116 ENSG00000141433 ADCYAP1 
adenylate 
cyclase 
activating 
polypeptide 1 
(pituitary) 
A_23_P148768 NA 2153 ENSG00000198734 F5 
coagulation 
factor V 
(proaccelerin, 
labile factor) 
A_23_P6335 NA 3053 ENSG00000099937 SERPIND1 
serpin 
peptidase 
inhibitor, 
clade D 
(heparin 
cofactor), 
member 1 
A_23_P407203 NA 9839 ENSG00000169554 ZEB2 
zinc finger E-
box binding 
homeobox 2 
A_23_P501319 NA 51666 ENSG00000005981 ASB4 
ankyrin repeat 
and SOCS 
box 
containing 4 
A_23_P213706 NA 3565 ENSG00000113520 IL4 interleukin 4 
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Table 5.1.3 (b) Transcription Target: hsa_V$NKX3A_01 DB_ID:2109 
C=232; O=4; E=0.23; R=17.70; rawP=7.78e-05; adjP=0.0019 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P110253 NA 3815 ENSG00000157404 KIT 
v-kit Hardy-
Zuckerman 4   
A_23_P410115 NA 150350 ENSG00000176177 ENTHD1 
ENTH domain 
containing 1 
A_23_P407203 NA 9839 ENSG00000169554 ZEB2 
zinc finger E-
box binding 
homeobox 2 
A_23_P501319 NA 51666 ENSG00000005981 ASB4 
ankyrin repeat 
and SOCS box 
containing 4 
 
5.1.4 KEGG pathway analysis 
42 probes were mapped to Entrez Ids out of 92 probes that were uploaded and their 
KEGG pathways are listed below (Table 5.1.4 a & b). Each gene was categorized based 
on its associated pathway and also the description of the function of the gene in that 
pathway was provided. The table shows the information on Entrez Id, Ensembl Id, Gene 
symbol and description for each of the probe Id that was uploaded. 
Table 5.1.4 (a) KEGG pathway: Cytokine-cytokine receptor interaction 04060 C=265; 
O=7; E=0.26; R=27.12; rawP=6.86e-09; adjP=1.17e-07 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P369815 NA 356 ENSG00000117560 FASLG 
Fas ligand 
(TNF 
superfamily, 
member 6) 
A_23_P93787 NA 3082 ENSG00000019991 HGF 
hepatocyte 
growth factor 
(hepapoietin 
A; scatter 
factor) 
A_24_P397817 NA 3952 ENSG00000174697 LEP leptin 
A_23_P57036 NA 958 ENSG00000101017 CD40 
CD40 
molecule, 
TNF receptor 
superfamily 
member 5 
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User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P110253 NA 3815 ENSG00000157404 KIT 
v-kit Hardy-
Zuckerman 4 
feline 
sarcoma viral 
oncogene 
homolog 
A_23_P30122 NA 3558 ENSG00000109471 IL2 interleukin 2 
A_23_P213706 NA 3565 ENSG00000113520 IL4 interleukin 4 
 
Table 5.1.4 (b) KEGG pathway: Allograft rejection 05330 C=37; O=4; E=0.04; 
R=111.01; rawP=5.01e-08; adjP=4.26e-07 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P369815 NA 356 ENSG00000117560 FASLG 
Fas ligand (TNF 
superfamily, 
member 6) 
A_23_P57036 NA 958 ENSG00000101017 CD40 
CD40 molecule, 
TNF receptor 
superfamily 
member 5 
A_23_P30122 NA 3558 ENSG00000109471 IL2 interleukin 2 
A_23_P213706 NA 3565 ENSG00000113520 IL4 interleukin 4 
 
The tables 5.1.2, 5.1.3, 5.1.4 are showing few genes and their GO, Transcription factor 
and KEGG pathways. The rest of the genes and their information are provided in the 
appendices. Each table is divided in to parts a & b as they differ in their functions.  
5.2 Results of analysis of cell lines treated only with BMP4 
5.2.1 Heat map 
Heat map was constructed in order to find out the up and down regulated genes using the 
list of genes from the top Table. Figure 5.2.1 shows about eighty one genes and their log 
FC values plotted against each other for each line. From the heat map it was seen that the 
genes followed different patterns of expression in each cell line. The red color indicates 
over expressed or up regulated genes while green color indicates under expressed or 
down regulated genes. There were nine genes that under expressed in all the cell lines.  
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Figure 5.2.1 Heat map showing up regulated and down regulated genes of BMP4     
signaling in cell lines                               
Heat map showing up regulated and down regulated genes of cell lines HCC_1419, 
SK_BR_30, HCC_1954, MDA_MB_361, ZR_75_30 treated with BMP4. A very few set 
of genes were found to under express and several genes were found to over express in all 
the five cell lines. Each row represents each gene, represented by its probe ID and the 
columns represent respective cell lines. The log FC values of each gene in each cell line 
was plotted in order to read the expression of genes. The heat map showing up regulated 
genes in red and down expressed genes in green and was identified as indicating 
different levels of expression of same gene but differing from cell line to cell line (Figure 
5.2.1). 
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There were seventy two genes in cell lines HCC_1954, HCC_1419, SK_BR_30, 
ZR_75_30 and MDA_MB_361 that showed over expression. The set of genes were also 
found to have biological functions when they were subjected to GO analysis. 
5.2.2 GO analysis 
Among 81 probe Ids that were uploaded, 33 probes were mapped to Entrez Ids. The GO 
analysis provided enriched GO categories under Biological processes, Molecular 
function and Cellular component. The following table (5.2.2 a & b) shows the set of 
genes and their biological functions. The genes were grouped under one biological 
process based on the values such as number of reference genes in the category (C), 
number of genes in the gene set and also in the category (O), expected number in the 
category (E), ratio of enrichment (R), p value from hypergeometric test (rawP) and p 
value adjusted by multiple test adjustment. Similarly the tables were obtained for 
Molecular functions and Cellular components using the same set of genes. 
Table 5.2.2 (a) Biological processes of GO analysis 
GO  Biological Process C   O  E R rawP adjP           
003085
5 
epithelial cell differentiation 307 7 0.55 12.83 7.81e-
07 
0.0003 
User Id Value 
Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P339691 NA 353135 ENSG00000186226 LCE1E 
late cornified 
envelope 1E 
A_32_P69368 NA 3398 ENSG00000115738 ID2 
inhibitor of 
DNA binding 
2, dominant 
negative helix-
loop-helix 
protein 
A_23_P151294 NA 3458 ENSG00000111537 IFNG 
interferon, 
gamma 
A_23_P252306 NA 3397 ENSG00000125968 ID1 
inhibitor of 
DNA binding 
1, dominant 
negative helix-
loop-helix 
protein 
A_23_P54100 NA 2100 ENSG00000140009 ESR2 
estrogen 
receptor 2 (ER 
beta) 
A_23_P72096 NA 3552 ENSG00000115008 IL1A 
interleukin 1, 
alpha 
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  Table 5.2.2 (b) 
GO  
 
Biological Process 
 
C 
 
O 
 
 E 
 
R 
 
rawP 
 
adjP       
  
0060429 epithelium development   604   9 1.07 8.38 5.46e-
07 
0.0003    
User Id Value 
Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P151294 NA 3458 ENSG00000111537 IFNG 
interferon, 
gamma 
A_23_P252306 NA 3397 ENSG00000125968 ID1 
inhibitor of DNA 
binding 1, 
dominant 
negative helix-
loop-helix 
protein 
A_23_P328074 NA 6299 ENSG00000103449 SALL1 
sal-like 1 
(Drosophila) 
5.2.3 Transcription Factor analysis 
There were 33 probes mapped with Entrez Ids out of 81 probes that were loaded. The 
table (5.2.3 a & b) shows significantly enriched gene sets. The Entrez genes were 
represented by Entrez Ids and the description defines about the gene. The following table 
defines each of the category by which the set of genes were categorized - number of 
reference genes in the category (C), number of genes in the gene set and also in the 
category (O), expected number in the category (E), ratio of enrichment (R), p value from 
hypergeometric test (rawP) and p value adjusted by multiple test adjustment. 
Table 5.2.3 (a) Transcription Target: hsa_V$FOXJ2_01 DB_ID:2088 C=181; O=3; 
E=0.14; R=21.66; rawP=0.0004; adjP=0.0107 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_32_P69368 NA 3398 ENSG00000115738 ID2 inhibitor of 
DNA binding 
2, dominant 
negative helix-
loop-helix 
protein 
A_23_P252306 NA 3397 ENSG00000125968 ID1 inhibitor of 
DNA binding 
1, dominant 
negative helix- 
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User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
     loop-helix 
protein 
A_24_P199484 NA 9068 ENSG00000116194 ANGPTL1 angiopoietin-
like 1 
 
Table 5.2.3 (b) Transcription Target: hsa_TATAAA_V$TATA_01 DB_ID:2456 
C=1276; O=6; E=0.98; R=6.15; rawP=0.0004; adjP=0.0107 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_32_P69368 NA 3398 ENSG00000115738 ID2 inhibitor of 
DNA 
binding 2, 
dominant 
negative 
helix-loop-
helix protein 
A_23_P151294 NA 3458 ENSG00000111537 IFNG interferon, 
gamma 
A_23_P252306 NA 3397 ENSG00000125968 ID1 inhibitor of 
DNA 
binding 1, 
dominant 
negative 
helix-loop-
helix protein 
A_23_P54100 NA 2100 ENSG00000140009 ESR2 estrogen 
receptor 2 
(ER beta) 
A_23_P87879 NA 969 ENSG00000110848 CD69 CD69 
molecule 
A_24_P199484 NA 9068 ENSG00000116194 ANGPTL
1 
angiopoietin-
like 1 
 
5.2.4 KEGG pathway analysis 
There were 33 probes that were mapped to Entrez Ids out of 81 probes and their KEGG 
pathways are listed below (Table 5.2.4 a, b & c). Each gene was categorized based on its 
associated pathway and also the description of the gene in that pathway was provided. 
The table shows the information on Entrez Id, Ensembl Id, Gene symbol and description 
for each of the probe Id that was uploaded. 
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Table 5.2.4 (a) KEGG pathway: Malaria 05144 C=51; O=3;E=0.04; R=76.88; 
rawP=8.29e-06; adjP=0.0001 
User Id Value 
Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P151294 NA 3458 ENSG00000111537 IFNG 
interferon, 
gamma 
A_23_P93787 NA 3082 ENSG00000019991 HGF 
hepatocyte 
growth factor 
(hepapoietin A; 
scatter factor) 
A_23_P60306 NA 7099 ENSG00000136869 TLR4 
toll-like receptor 
4 
 
Table 5.2.4 (b) KEGG pathway: Cytokine-cytokine receptor interaction 04060 C=265; 
O=4; E=0.20; R=19.73; rawP=4.96e-05; adjP=0.0002 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P151294 NA 3458 ENSG00000111537 IFNG 
interferon, 
gamma 
A_23_P60373 NA 3467 ENSG00000177047 IFNW1 
interferon, 
omega 1 
A_23_P93787 NA 3082 ENSG00000019991 HGF 
hepatocyte 
growth factor 
(hepapoietin A; 
scatter factor) 
A_23_P72096 NA 3552 ENSG00000115008 IL1A 
interleukin 1, 
alpha 
 
Table 5.2.4 (c) KEGG pathway: Rheumatoid arthritis 05323 C=91; O=3; E=0.07; 
R=43.08; rawP=4.74e-05; adjP=0.0002 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P151294 NA 3458 ENSG00000111537 IFNG 
interferon, 
gamma 
A_23_P72096 NA 3552 ENSG00000115008 IL1A 
interleukin 1, 
alpha 
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5.3 Group C genes analysis 
5.3.1 GO analysis 
From the 210 probes loaded for the analysis, 119 were mapped to be Entrez user Ids. The 
GO analysis provided enriched GO categories under Biological processes, Molecular 
function and Cellular component. The following table (5.3.1) shows the set of genes and 
their biological functions. The genes were grouped under one biological process based 
on the values - number of reference genes in the category (C), number of genes in the 
gene set and also in the category (O), expected number in the category (E), ratio of 
enrichment (R), p value from hypergeometric test (rawP) and p value adjusted by 
multiple test adjustment. Similarly the tables were obtained for set of genes for 
Molecular functions and Cellular components.  
Table 5.3.1 Biological processes of GO analysis 
GO  Biological Process C   O  E R rawP adjP           
0050789 Regulation of biological 
process 
8132 70 50.58 1.38 1.82 e-
05 
0.0075 
User Id Value 
Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_24_P14731 NA 27344 ENSG00000102109 PCSK1N 
proprotein 
convertase 
subtilisin/kexin 
type 1 inhibitor 
A_24_P416595 NA 284346 ENSG00000176472 ZNF575 
zinc finger protein 
575 
A_24_P113725 NA 6658 ENSG00000134595 SOX3 
SRY (sex 
determining region 
Y)-box 3 
A_24_P213884 NA 7148 ENSG00000168477 TNXB tenascin XB 
A_24_P216165 NA 1050 ENSG00000245848 CEBPA 
CCAAT/enhancer 
binding protein 
(C/EBP), alpha 
A_23_P54573 NA 161882 ENSG00000179588 ZFPM1 
zinc finger protein, 
multitype 1 
A_24_P44916 NA 148170 ENSG00000167617 CDC42EP5 
CDC42 effector 
protein (Rho 
GTPase binding) 5 
A_24_P279060 NA 10021 ENSG00000138622 HCN4 
hyperpolarization 
activated cyclic 
nucleotide-gated 
potassium channel 
4 
A_24_P10674 NA 115703 ENSG00000004777 ARHGAP33 
Rho GTPase 
activating protein  
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User Id Value 
Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
     33 
A_24_P878992 NA 10297 ENSG00000115266 APC2 
adenomatosis 
polyposis coli 2 
A_24_P203315 NA 254263 ENSG00000174871 CNIH2 
cornichon 
homolog 2 
(Drosophila) 
A_24_P251040 NA 9048 ENSG00000117407 ARTN artemin 
5.3.2 Transcription Factor analysis 
There were 119 probes mapped with Entrez Ids out of 210 probes that were loaded. The 
table shows significantly enriched gene sets. The Entrez genes were represented by 
Entrez Ids and the description defines about the gene. The following table (5.3.2) defines 
each of the category by which the set of genes were categorized - number of reference 
genes in the category (C), number of genes in the gene set and also in the category (O), 
expected number in the category (E), ratio of enrichment (R), p value from 
hypergeometric test (rawP) and p value adjusted by multiple test adjustment. 
Table 5.3.2 Transcription Target: hsa_CAGGTG_V$E12_Q6 DB_ID:2409 
C=2450; O=30; E=6.70; R=4.48; rawP=2.55e-12; adjP=8.64e-10 
User Id Value 
Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_24_P416595 NA 284346 ENSG00000176472 ZNF575 
zinc finger 
protein 575 
A_24_P43959 NA 55691 ENSG00000151474 FRMD4A 
FERM domain 
containing 4A 
A_24_P227326 NA 283248 ENSG00000167771 RCOR2 
REST 
corepressor 2 
A_23_P34554 NA 777 ENSG00000198216 CACNA1E 
calcium 
channel, 
voltage-
dependent, R 
type, alpha 1E 
subunit 
A_24_P117782 NA 85508 ENSG00000215397 SCRT2 
scratch 
homolog 2, 
zinc finger 
protein 
(Drosophila) 
A_24_P328446 NA 3196 ENSG00000115297 TLX2 
T-cell 
leukemia 
homeobox 2 
A_24_P113725 NA 6658 ENSG00000134595 SOX3 
SRY (sex 
determining 
region Y)-box  
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User Id Value 
Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
     3 
A_23_P96072 NA 2902 ENSG00000176884 GRIN1 
glutamate 
receptor, 
ionotropic, N-
methyl D-
aspartate 1 
5.3.3 KEGG pathway analysis 
There were 119 probes that were mapped to Entrez Ids out of 210 probes and their 
KEGG pathways are listed below (Table 5.3.3). Each gene was categorized based on its 
associated pathway and also the description of the gene was provided. The table shows 
the information on Entrez Id, Ensembl Id, Gene symbol and description for each of the 
probe Id that was uploaded. 
Table 5.3.3 KEGG pathway: Neuroactive ligand-receptor interaction 04080 C=272; 
O=6; E=0.74; R=8.06; rawP=0.0001; adjP=0.0014 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P153549 NA 2906 ENSG00000105464 GRIN2D 
glutamate 
receptor, 
ionotropic, N-
methyl D-
aspartate 2D 
A_23_P146885 NA 2837 ENSG00000181408 UTS2R 
urotensin 2 
receptor 
A_23_P150162 NA 1815 ENSG00000069696 DRD4 
dopamine 
receptor D4 
A_23_P20458 NA 2831 ENSG00000183729 NPBWR1 
neuropeptides 
B/W receptor 1 
A_23_P101761 NA 84634 ENSG00000116014 KISS1R KISS1 receptor 
A_23_P96072 NA 2902 ENSG00000176884 GRIN1 
glutamate 
receptor, 
ionotropic, N-
methyl D-
aspartate 1 
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6. DISCUSSION 
6.1 Analysis of cell lines treated with both BMP4 and BMP7 
This analysis showed number of genes that were regulated by BMP4 and BMP7 
treatment. The signaling effect of both ligands together on these genes was found to vary 
between cell line to cell line. A set of genes showed over expression in two cell lines and 
under expression in one cell line. Another set of genes remained under expressed in two 
cell lines and over expressed in one cell line (Figure 5.1.1). This indicates the possibility 
of influence of one ligand over the other, thereby making dissimilar expression of genes 
in all the three cell lines. The GO analysis of these genes showed their biological process 
such as positive regulation of isotype switching, peptidyl-tyrosine modification, peptidyl-
tyrosine phosphorylation, positive regulation of DNA regulation, peptide hormone 
receptor binding. The molecular functions were peptidase activity, growth factor activity, 
heparin binding, carbohydrate derivative binding, SMAD binding and enzyme binding. 
The pathways such as T cell receptor signaling pathway, pathways in cancer, primary 
immunodeficiency and autoimmune thyroid disease were found to be involving these 
genes. 
 The variable expression of BMPs in primary breast cancer samples and cell lines were 
demonstrated by Alarmo et al., 2010 had shown that the BMP4 and BMP7 were 
expressed in majority in both cell lines and primary breast cancer samples and the levels 
of expression in normal cells were relatively less. The expression had widely targeted the 
genes in both cell line and samples. These genes when studied further may help to find 
out highly regulated gene and its network thereby in finding out the mechanism of action 
of BMP4 and BMP7. It can be said that the genes showed a contrast in expression in 
each cell line but shows essential information like pathways involved. 
6.2 Analysis of cell lines treated only with BMP4  
As BMP4 is widely studied for its role in cancer, the main focus of this thesis was to find 
out the genes responding to BMP4 treatment. It was seen that there were eighty one 
genes totally responding to the ligand. Nine genes were found to be under expressed in 
all the five cell lines showing uniform expression and seventy two genes were found to 
over express in all the five cell lines (Figure 5.2.1). Further, GO analysis of these genes 
showed their role in biological functions like Interleukin-1 production, Cytokine 
metabolic process, positive regulation of MHC class II biosynthetic process and 
epithelium development. The molecular functions were receptor binding, cytokine 
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activity, Serine-type endopeptidase activity and many more. KEGG pathways like TGF-
beta signaling pathway, melanoma and Graft-versus-host disease were noticed involving 
these genes. These results indicate that the role of these genes in TGF-signaling pathway 
may be altered upon BMP4 treatment. If the network of pathways when studied, can 
bring out the interactions of these genes in the pathway and also the risk of diseases 
associated when these genes are not regulated.  
 
The validation with primary breast cancer samples from database would bring about the 
comparison of these genes and their expression both at cell line and tissue samples there 
by establishing a comparison between in vivo and in vitro conditions playing a role in 
their expression. Earlier a comparative work was carried out by Alarmo et al., 2010 had 
shown the effect of BMP4. It was reported that BMP4 had shown elevated levels of 
expression in primary tumors and cell lines when compared to all the other BMPs. 
Rodriguez-Martinez et al., 2011 had reported the transcriptional regulation that leads to 
metabolic changes and cell proliferation in breast cancer cell lines. Hence, a comparative 
study with the genes that have been found out from this work can bring about some 
highly regulated genes of BMP4. Having used a microarray platform, the experiment has 
wider scope for comparison with other data sets that are also from same Agilent 
platform. Bioconductor would serve as a potential tool in comparison steps and can bring 
about new findings. On the whole, it can be said that this work had focused on throwing 
light on the genes that were regulated by BMP4 and BMP7 treatments and also provides 
a scenario for works in future.  
 
Finding out the most responsive genes to BMP4 and its transcriptional responses would 
bring in some potential targets that may be developed as therapeutic agents for breast 
cancer and it may also serve in understanding the unrevealed mechanism of BMP4 in 
breast cancer. Webgestalt can be used in order to investigate disease association, drug 
association and also microRNA target analysis. It is essential in cancer studies to relate 
diseases associated to gene and its function. The malfunctioning of a gene may cause 
disease and by understanding this relationship, developing drugs would become easier.  
 
46 
 
6.3 Analysis of group C genes 
The analysis of group C genes was carried out with an intention to find out the 
biological, molecular and cellular functions of the genes. The genes were found 
interesting from the data set as they were the synexpression group of genes. 
Synexpression group of genes are known to be involved in the same process and are all 
coordinately expressed and are found to have common cis and trans acting elements. 
There were 210 probes of which 119 were mapped to Entrez Ids that is found to be 
Entrez annotated genes.  
 
The Gene Ontology analysis of the probes showed their role in essential biological 
processes like regulation of biological processes, epithelium development of kidney, 
positive regulation of transcription from RNA polymerase II promoter, regulation of 
multicellular organismal process, cellular nitrogen compound biosynthetic process and 
nephron epithelium morphogenesis. The molecular functions in which these genes 
involved are nucleic acid binding transcription factor activity, sequence-specific DNA 
binding transcription factor activity, DNA binding, sequence-specific DNA binding, 
RNA polymerase II distal enhancer sequence-specific DNA binding transcription factor 
activity, sequence-specific DNA binding RNA polymerase II transcription factor 
activity, nucleic acid binding and double-stranded DNA binding.  
 
It is seen that all these processes are closely associated to transcription and it can said 
that the genes that had showed response to BMP4 and BMP7 treatment are all regulatory 
genes in nature and these two ligands had very strong effect on transcription process of 
these genes. Few of the pathways that are related to these genes are basal cell carcinoma 
pathway, cancer pathways and Wnt signaling pathway. These information help to find 
out the genes that play a major role in these pathways and by altering its expression 
defective pathways can be made functional and thereby preventing a non-functional 
pathway leading to diseases. These genes were found to be expressed in cell lines but 
their expression in primary breast cancer samples still remains unexplored. However, in 
future studies can be focused on these genes to find out their activities in tumor cells. 
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7. CONCLUSION 
This work was an attempt towards finding out the target genes from the most regulated 
genes of BMP4 and BMP7 signaling. From the heat map results it was seen that there 
were a set of genes that formed clusters and showed expression to BMP4 and BMP7 
signaling. Similarly there were clusters of genes that showed expression upon treatment 
only with BMP4. There were ninety three genes that showed expression upon BMP4 and 
BMP7 treatment and in case of BMP4 treatment it was eighty one genes. The results 
established the effect of influence of these ligands on the target genes. Further, validation 
of these genes would result in acquiring exactly or highly regulated genes by BMP4 and 
BMP7 signaling. From this work, the GO analysis, Transcription Factor analysis and 
KEGG pathways of the genes provide information on each gene and its role in 
transcription. As BMP4 is much studied for its role in transcriptional responses in these 
cell lines, the transcription factor analysis would bring in new insights on BMP4’s 
transcriptional effect. These analytical studies indicated the role of genes in major 
pathways and also their role in many molecular processes. On the whole, the work 
attempted at bringing out the genes and their role when treated with ligands like BMP4 
and BMP7.  
The analysis of group C genes was made to find out further information as they were 
showing strong response to both BMP4 and BMP7. They contributed to a large set of 
genes about hundred and nineteen genes and they were all found to be involved in 
pathways like Wnt signaling pathway, basal cell carcinoma and many pathways in 
cancer. All these results from the work had created a basic incite to further explore on 
genes regulated by signaling of BMP4 and BMP7.  
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 9. APPENDICES 
  9.1 Analysis of cell lines treated with both BMP4 and BMP7 
  9.1.1 Tables showing results of GO analysis 
 
Biological process: positive regulation of isotype switching to IgG isotypes  
GO:0048304 C=7;O=4;E=0.01;R=269.68;rawP=5.75e-10;adjP=3.97e-07 
User Id Value Entrez ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P125451 NA 5788 ENSG00000081237 PTPRC 
protein 
tyrosine 
phosphatase, 
receptor type, 
C 
A_23_P57036 NA 958 ENSG00000101017 CD40 
CD40 
molecule, 
TNF receptor 
superfamily 
member 5 
A_23_P30122 NA 3558 ENSG00000109471 IL2 interleukin 2 
A_23_P213706 NA 3565 ENSG00000113520 IL4 interleukin 4 
 
 
Biological process: peptidyl-tyrosine phosphorylation  
GO:0018108 C=201;O=8;E=0.43;R=18.78;rawP=6.64e-09;adjP=9.29e-07 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P125451 NA 5788 ENSG00000081237 PTPRC 
protein 
tyrosine 
phosphatase, 
receptor type, 
C 
A_23_P93787 NA 3082 ENSG00000019991 HGF 
hepatocyte 
growth factor 
(hepapoietin 
A; scatter 
factor) 
A_24_P397817 NA 3952 ENSG00000174697 LEP leptin 
A_23_P57036 NA 958 ENSG00000101017 CD40 
CD40 
molecule, 
TNF receptor 
superfamily 
member 5 
A_23_P110253 NA 3815 ENSG00000157404 KIT 
v-kit Hardy-
Zuckerman 4 
feline 
sarcoma viral 
oncogene 
homolog 
A_23_P39682 NA 7535 ENSG00000115085 ZAP70 
zeta-chain 
(TCR)  
57 
 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
     
associated 
protein 
kinase 70kDa 
A_23_P30122 NA 3558 ENSG00000109471 IL2 interleukin 2 
A_23_P213706 NA 3565 ENSG00000113520 IL4 interleukin 4 
 
 
Biological process: peptidyl-tyrosine modification  
GO:0018212 C=203;O=8;E=0.43;R=18.60;rawP=7.18e-09;adjP=9.29e-07 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P125451 NA 5788 ENSG00000081237 PTPRC 
protein 
tyrosine 
phosphatase, 
receptor type, 
C 
A_23_P93787 NA 3082 ENSG00000019991 HGF 
hepatocyte 
growth factor 
(hepapoietin 
A; scatter 
factor) 
A_24_P397817 NA 3952 ENSG00000174697 LEP leptin 
A_23_P57036 NA 958 ENSG00000101017 CD40 
CD40 
molecule, 
TNF receptor 
superfamily 
member 5 
A_23_P110253 NA 3815 ENSG00000157404 KIT 
v-kit Hardy-
Zuckerman 4 
feline 
sarcoma viral 
oncogene 
homolog 
A_23_P39682 NA 7535 ENSG00000115085 ZAP70 
zeta-chain 
(TCR) 
associated 
protein 
kinase 70kDa 
A_23_P30122 NA 3558 ENSG00000109471 IL2 interleukin 2 
A_23_P213706 NA 3565 ENSG00000113520 IL4 interleukin 4 
 
 
Biological process: positive regulation of isotype switching  
GO:0045830 C=12;O=4;E=0.03;R=157.31;rawP=8.07e-09;adjP=9.29e-07 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P125451 NA 5788 ENSG00000081237 PTPRC 
protein 
tyrosine 
phosphatase, 
receptor type, 
C 
A_23_P57036 NA 958 ENSG00000101017 CD40 CD40  
58 
 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
     
molecule, 
TNF receptor 
superfamily 
member 5 
A_23_P30122 NA 3558 ENSG00000109471 IL2 interleukin 2 
A_23_P213706 NA 3565 ENSG00000113520 IL4 interleukin 4 
A_23_P30122 NA 3558 ENSG00000109471 IL2 interleukin 2 
A_23_P213706 NA 3565 ENSG00000113520 IL4 interleukin 4 
 
 
Biological process: positive regulation of tyrosine phosphorylation of STAT protein 
GO:0042531 C=42;O=5;E=0.09;R=56.18;rawP=2.45e-08;adjP=2.12e-06 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_24_P397817 NA 3952 ENSG00000174697 LEP leptin 
A_23_P57036 NA 958 ENSG00000101017 CD40 
CD40 
molecule, 
TNF receptor 
superfamily 
member 5 
A_23_P110253 NA 3815 ENSG00000157404 KIT 
v-kit Hardy-
Zuckerman 4 
feline 
sarcoma viral 
oncogene 
homolog 
A_23_P30122 NA 3558 ENSG00000109471 IL2 interleukin 2 
A_23_P213706 NA 3565 ENSG00000113520 IL4 interleukin 4 
 
  9.1.2 Tables showing results of Transcription Factor analysis 
 
Transcription Target: hsa_TGCTGAY_UNKNOWN DB_ID:2367 
C=530;O=6;E=0.52;R=11.62;rawP=1.21e-05;adjP=0.0012 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_24_P335781 NA 116 ENSG00000141433 ADCYAP1 
adenylate 
cyclase 
activating 
polypeptide 1 
(pituitary) 
A_23_P148768 NA 2153 ENSG00000198734 F5 
coagulation 
factor V 
(proaccelerin, 
labile factor) 
A_23_P407203 NA 9839 ENSG00000169554 ZEB2 
zinc finger E-
box binding 
homeobox 2 
A_23_P501319 NA 51666 ENSG00000005981 ASB4 
ankyrin repeat 
and SOCS 
box 
containing 4 
59 
 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P213706 NA 3565 ENSG00000113520 IL4 interleukin 4 
 
 
Transcription Target: hsa_V$NKX3A_01 DB_ID:2109 
C=232;O=4;E=0.23;R=17.70;rawP=7.78e-05;adjP=0.0019 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P110253 NA 3815 ENSG00000157404 KIT 
v-kit Hardy-
Zuckerman 4 
feline 
sarcoma viral 
oncogene 
homolog 
A_23_P410115 NA 150350 ENSG00000176177 ENTHD1 
ENTH 
domain 
containing 1 
A_23_P407203 NA 9839 ENSG00000169554 ZEB2 
zinc finger 
E-box 
binding 
homeobox 2 
A_23_P501319 NA 51666 ENSG00000005981 ASB4 
ankyrin 
repeat and 
SOCS box 
containing 4 
 
 
Transcription Target: hsa_CAGGTA_V$AREB6_01 DB_ID:2404 
C=780;O=6;E=0.76;R=7.90;rawP=0.0001;adjP=0.0019 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P93787 NA 3082 ENSG00000019991 HGF 
hepatocyte 
growth factor 
(hepapoietin 
A; scatter 
factor) 
A_23_P57036 NA 958 ENSG00000101017 CD40 
CD40 
molecule, 
TNF receptor 
superfamily 
member 5 
A_23_P54100 NA 2100 ENSG00000140009 ESR2 
estrogen 
receptor 2 
(ER beta) 
A_24_P944741 NA 55805 ENSG00000109771 LRP2BP 
LRP2 
binding 
protein 
A_23_P30122 NA 3558 ENSG00000109471 IL2 interleukin 2 
A_23_P407203 NA 9839 ENSG00000169554 ZEB2 
zinc finger E-
box binding 
homeobox 2 
A_24_P135769 NA 4013 ENSG00000110002 VWA5A 
von 
Willebrand  
60 
 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
     
factor A 
domain 
containing 
5A 
A_23_P30122 NA 3558 ENSG00000109471 IL2 interleukin 2 
A_23_P407203 NA 9839 ENSG00000169554 ZEB2 
zinc finger E-
box binding 
homeobox 2 
 
 
Transcription Target: hsa_TGCCAAR_V$NF1_Q6 DB_ID:2436 
C=709;O=5;E=0.69;R=7.24;rawP=0.0006;adjP=0.0065 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P93787 NA 3082 ENSG00000019991 HGF 
hepatocyte 
growth factor 
(hepapoietin 
A; scatter 
factor) 
A_23_P259003 NA 51555 ENSG00000114757 PEX5L 
peroxisomal 
biogenesis 
factor 5-like 
A_24_P335781 NA 116 ENSG00000141433 ADCYAP1 
adenylate 
cyclase 
activating 
polypeptide 
1 (pituitary) 
A_23_P110253 NA 3815 ENSG00000157404 KIT 
v-kit Hardy-
Zuckerman 4 
feline 
sarcoma viral 
oncogene 
homolog 
A_23_P407203 NA 9839 ENSG00000169554 ZEB2 
zinc finger 
E-box 
binding 
homeobox 2 
 
 
Transcription Target: hsa_GATTGGY_V$NFY_Q6_01 DB_ID:2440 
C=1141;O=6;E=1.11;R=5.40;rawP=0.0008;adjP=0.0078 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P57036 NA 958 ENSG00000101017 CD40 
CD40 
molecule, 
TNF receptor 
superfamily 
member 5 
 
A_23_P114934 NA 84944 ENSG00000143194 MAEL 
maelstrom 
homolog 
(Drosophila) 
61 
 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_24_P944741 NA 55805 ENSG00000109771 LRP2BP 
LRP2 
binding 
protein 
A_23_P368182 NA 254428 ENSG00000133065 SLC41A1 
solute carrier 
family 41, 
member 1 
A_23_P407203 NA 9839 ENSG00000169554 ZEB2 
zinc finger E-
box binding 
homeobox 2 
A_23_P213706 NA 3565 ENSG00000113520 IL4 interleukin 4 
 
 
  9.1.3 Tables showing results of KEGG pathway analysis 
 
KEGG pathway: Cytokine-cytokine receptor interaction 04060 
C=265;O=7;E=0.26;R=27.12;rawP=6.86e-09;adjP=1.17e-07 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P369815 NA 356 ENSG00000117560 FASLG 
Fas ligand 
(TNF 
superfamily, 
member 6) 
A_23_P93787 NA 3082 ENSG00000019991 HGF 
hepatocyte 
growth factor 
(hepapoietin 
A; scatter 
factor) 
A_24_P397817 NA 3952 ENSG00000174697 LEP leptin 
A_23_P57036 NA 958 ENSG00000101017 CD40 
CD40 
molecule, 
TNF receptor 
superfamily 
member 5 
A_23_P110253 NA 3815 ENSG00000157404 KIT 
v-kit Hardy-
Zuckerman 4 
feline 
sarcoma viral 
oncogene 
homolog 
A_23_P30122 NA 3558 ENSG00000109471 IL2 interleukin 2 
A_23_P213706 NA 3565 ENSG00000113520 IL4 interleukin 4 
 
 
KEGG pathway: Autoimmune thyroid disease 05320 
C=52;O=4;E=0.05;R=78.99;rawP=2.03e-07;adjP=1.15e-06 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P369815 NA 356 ENSG00000117560 FASLG 
Fas ligand 
(TNF 
superfamily, 
member 6) 
62 
 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P57036 NA 958 ENSG00000101017 CD40 
CD40 
molecule, 
TNF receptor 
superfamily 
member 5 
A_23_P30122 NA 3558 ENSG00000109471 IL2 interleukin 2 
A_23_P213706 NA 3565 ENSG00000113520 IL4 interleukin 4 
 
 
KEGG pathway: T cell receptor signaling pathway 04660 
C=108;O=4;E=0.11;R=38.03;rawP=3.87e-06;adjP=1.64e-05 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P125451 NA 5788 ENSG00000081237 PTPRC 
protein 
tyrosine 
phosphatase, 
receptor type, 
C 
A_23_P39682 NA 7535 ENSG00000115085 ZAP70 
zeta-chain 
(TCR) 
associated 
protein 
kinase 70kDa 
A_23_P30122 NA 3558 ENSG00000109471 IL2 interleukin 2 
A_23_P213706 NA 3565 ENSG00000113520 IL4 interleukin 4 
 
  
KEGG pathway: Primary immunodeficiency 05340 
C=35;O=3;E=0.03;R=88.01;rawP=5.50e-06;adjP=1.87e-05 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P125451 NA 5788 ENSG00000081237 PTPRC 
protein 
tyrosine 
phosphatase, 
receptor type, 
C 
A_23_P57036 NA 958 ENSG00000101017 CD40 
CD40 
molecule, 
TNF receptor 
superfamily 
member 5 
A_23_P39682 NA 7535 ENSG00000115085 ZAP70 
zeta-chain 
(TCR) 
associated 
protein 
kinase 70kDa 
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KEGG pathway: Intestinal immune network for IgA production 04672 
C=48;O=3;E=0.05;R=64.18;rawP=1.44e-05;adjP=4.08e-05 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P57036 NA 958 ENSG00000101017 CD40 
CD40 
molecule,  
A_23_P30122 NA 3558 ENSG00000109471 IL2 interleukin 2 
A_23_P213706 NA 3565 ENSG00000113520 IL4 interleukin 4 
 
 
KEGG pathway: Pathways in cancer 05200 
C=326;O=4;E=0.32;R=12.60;rawP=0.0003;adjP=0.0007 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P369815 NA 356 ENSG00000117560 FASLG 
Fas ligand 
(TNF 
superfamily, 
member 6) 
A_23_P93787 NA 3082 ENSG00000019991 HGF 
hepatocyte 
growth factor 
(hepapoietin 
A; scatter 
factor) 
A_23_P110253 NA 3815 ENSG00000157404 KIT 
v-kit Hardy-
Zuckerman 4 
feline 
sarcoma viral 
oncogene 
homolog 
A_23_P98898 NA 1017 ENSG00000123374 CDK2 
cyclin-
dependent 
kinase 2 
 
 
KEGG pathway: Asthma 05310 
C=30;O=2;E=0.03;R=68.46;rawP=0.0004;adjP=0.0009 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P57036 NA 958 ENSG00000101017 CD40 
CD40 
molecule, 
TNF receptor 
superfamily 
member 5 
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  9.2 Analysis of cell lines treated only with BMP4 
  9.2.1 Tables showing results of GO analysis      
Biological process: epithelial cell differentiation 
GO:0030855 C=307;O=7;E=0.55;R=12.83;rawP=7.81e-07;adjP=0.0003 
  
User Id Value 
Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P339691 NA 353135 ENSG00000186226 LCE1E 
late 
cornified 
envelope 1E 
A_32_P69368 NA 3398 ENSG00000115738 ID2 
inhibitor of 
DNA 
binding 2, 
dominant 
negative 
helix-loop-
helix protein 
A_23_P151294 NA 3458 ENSG00000111537 IFNG 
interferon, 
gamma 
A_23_P252306 NA 3397 ENSG00000125968 ID1 
inhibitor of 
DNA 
binding 1, 
dominant 
negative 
helix-loop-
helix protein 
A_23_P54100 NA 2100 ENSG00000140009 ESR2 
estrogen 
receptor 2 
(ER beta) 
A_23_P72096 NA 3552 ENSG00000115008 IL1A 
interleukin 
1, alpha 
A_23_P328074 NA 6299 ENSG00000103449 SALL1 
sal-like 1 
(Drosophila) 
      
      
Biological process: epithelium development  
GO:0060429 C=604;O=9;E=1.07;R=8.38;rawP=5.46e-07;adjP=0.0003 
  
User Id Value 
Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P151294 NA 3458 ENSG00000111537 IFNG 
interferon, 
gamma 
A_23_P252306 NA 3397 ENSG00000125968 ID1 
inhibitor of 
DNA 
binding 1, 
dominant 
negative  
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User Id Value 
Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
     
helix-loop-
helix protein 
A_23_P328074 NA 6299 ENSG00000103449 SALL1 
sal-like 1 
(Drosophila) 
A_32_P69368 NA 3398 ENSG00000115738 ID2 
inhibitor of 
DNA 
binding 2, 
dominant 
negative 
helix-loop-
helix protein 
A_24_P99244 NA 2252 ENSG00000140285 FGF7 
fibroblast 
growth 
factor 7 
A_23_P339691 NA 353135 ENSG00000186226 LCE1E 
late 
cornified 
envelope 1E 
A_23_P93787 NA 3082 ENSG00000019991 HGF 
"hepatocyte 
growth 
factor 
(hepapoietin 
A; scatter 
factor)" 
A_23_P72096 NA 3552 ENSG00000115008 IL1A 
interleukin 
1, alpha 
A_23_P54100 NA 2100 ENSG00000140009 ESR2 
estrogen 
receptor 2 
(ER beta) 
     
      
Biological process: Regulation of steroid metabolic process  
GO:0019218 C=67;O=4;E=0.12;R=33.59;rawP=5.57e-06;adjP=0.0013 
User Id Valu
e 
Entre
z ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P1512
94 
NA 3458 ENSG000001115
37 
IFNG interferon, gamma 
      
A_23_P7209
6 
NA 3552 ENSG000001150
08 
IL1A interleukin 1, alpha 
      
A_23_P7959
1 
NA 338 ENSG000000846
74 
APOB apolipoprotein B 
(including Ag(x) 
antigen) 
A_24_P2392
66 
NA 55004 ENSG000001493
57 
LAMTOR
1 
late 
endosomal/lysoso
mal adaptor, 
MAPK and MTOR 
66 
 
activator 1 
 
Biological process: Epithelial cell development  
GO:0002064 C=82;O=4;E=0.15;R=27.45;rawP=1.25e-05;adjP=0.0021 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P151294 NA 3458 ENSG00000111537 IFNG interferon, 
gamma 
A_23_P252306 NA 3397 ENSG00000125968 ID1 inhibitor of 
DNA 
binding 1, 
dominant 
negative 
helix-loop-
helix protein 
A_23_P54100 NA 2100 ENSG00000140009 ESR2 estrogen 
receptor 2 
(ER beta) 
A_23_P328074 NA 6299 ENSG00000103449 SALL1 sal-like 1 
(Drosophila) 
      
      
Biological process: Positive regulation of MHC class II biosynthetic process 
GO:0045348 C=8;O=2;E=0.01;R=140.67;rawP=8.45e-05;adjP=0.0027 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P151294 NA 3458 ENSG00000111537 IFNG interferon, 
gamma 
A_23_P60306 NA 7099 ENSG00000136869 TLR4 toll-like 
receptor 4 
 
  9.2.2 Tables showing results of Transcription Factor analysis 
Transcription Target: hsa_V$FOXJ2_01 DB_ID:2088 
C=181;O=3;E=0.14;R=21.66;rawP=0.0004;adjP=0.0107 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_32_P69368 NA 3398 ENSG00000115738 ID2 inhibitor of 
DNA binding 
2, dominant 
negative 
helix-loop-
helix protein 
A_23_P252306 NA 3397 ENSG00000125968 ID1 inhibitor of 
DNA binding 
1, dominant 
negative 
helix-loop-
helix protein 
A_24_P199484 NA 9068 ENSG00000116194 ANGPTL1 angiopoietin-
67 
 
like 1 
 
Transcription Target: hsa_TATAAA_V$TATA_01 DB_ID:2456 
C=1276;O=6;E=0.98;R=6.15;rawP=0.0004;adjP=0.0107 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_32_P69368 NA 3398 ENSG00000115738 ID2 inhibitor of 
DNA binding 
2, dominant 
negative 
helix-loop-
helix protein 
A_23_P151294 NA 3458 ENSG00000111537 IFNG interferon, 
gamma 
A_23_P252306 NA 3397 ENSG00000125968 ID1 inhibitor of 
DNA binding 
1, dominant 
negative 
helix-loop-
helix protein 
A_23_P54100 NA 2100 ENSG00000140009 ESR2 estrogen 
receptor 2 
(ER beta) 
A_23_P87879 NA 969 ENSG00000110848 CD69 CD69 
molecule 
A_24_P199484 NA 9068 ENSG00000116194 ANGPTL1 angiopoietin-
like 1 
 
Transcription Target: hsa_V$HFH4_01 DB_ID:2237 
C=195;O=3;E=0.15;R=20.11;rawP=0.0004;adjP=0.0107 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_32_P69368 NA 3398 ENSG00000115738 ID2 inhibitor of 
DNA binding 
2, dominant 
negative 
helix-loop-
helix protein 
A_23_P252306 NA 3397 ENSG00000125968 ID1 inhibitor of 
DNA binding 
1, dominant 
negative 
helix-loop-
helix protein 
A_24_P199484 NA 9068 ENSG00000116194 ANGPTL1 angiopoietin-
like 1 
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Transcription Target: hsa_GTCNYYATGR_UNKNOWN DB_ID:2335 
C=108;O=2;E=0.08;R=24.20;rawP=0.0031;adjP=0.0248 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P252306 NA 3397 ENSG00000125968 ID1 inhibitor of 
DNA binding 
1, dominant 
negative 
helix-loop-
helix protein 
A_23_P328074 NA 6299 ENSG00000103449 SALL1 sal-like 1 
(Drosophila) 
 
Transcription Target: hsa_CAGGTA_V$AREB6_01 DB_ID:2404 
C=780;O=4;E=0.60;R=6.70;rawP=0.0029;adjP=0.0248 
User Id Valu
e 
Entre
z ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P93787 NA 3082 ENSG0000001999
1 
HGF hepatocyte growth 
factor (hepapoietin 
A; scatter factor) 
A_23_P54100 NA 2100 ENSG0000014000
9 
ESR2 estrogen receptor 2 
(ER beta) 
A_32_P83556
6 
NA 401024 ENSG0000018873
8 
FSIP2 fibrous sheath 
interacting protein 2 
A_24_P23926
6 
NA 55004 ENSG0000014935
7 
LAMTOR
1 
late 
endosomal/lysosoma
l adaptor, MAPK 
and MTOR activator 
1 
 
Transcription Target: hsa_AAAYRNCTG_UNKNOWN DB_ID:1846 
C=368;O=3;E=0.28;R=10.65;rawP=0.0028;adjP=0.0248 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P93787 NA 3082 ENSG00000019991 HGF hepatocyte 
growth factor 
(hepapoietin 
A; scatter 
factor) 
A_23_P252306 NA 3397 ENSG00000125968 ID1 inhibitor of 
DNA binding 
1, dominant 
negative 
helix-loop-
helix protein 
A_32_P835566 NA 401024 ENSG00000188738 FSIP2 fibrous sheath 
interacting 
protein 2 
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  9.2.3 Tables showing results of KEGG pathway analysis 
 
KEGG pathway: Rheumatoid arthritis  
05323 C=91;O=3;E=0.07;R=43.08;rawP=4.74e-05;adjP=0.0002 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P151294 NA 3458 ENSG00000111537 IFNG 
interferon, 
gamma 
A_23_P72096 NA 3552 ENSG00000115008 IL1A 
interleukin 1, 
alpha 
A_23_P60306 NA 7099 ENSG00000136869 TLR4 
toll-like 
receptor 4 
 
KEGG pathway: Leishmaniasis  
05140 C=72;O=3;E=0.06;R=54.45;rawP=2.35e-05;adjP=0.0002 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P151294 NA 3458 ENSG00000111537 IFNG 
interferon, 
gamma 
A_23_P72096 NA 3552 ENSG00000115008 IL1A 
interleukin 1, 
alpha 
A_23_P60306 NA 7099 ENSG00000136869 TLR4 
toll-like 
receptor 4 
 
KEGG pathway: TGF-beta signaling pathway  
04350 C=84;O=3;E=0.06;R=46.67;rawP=3.73e-05;adjP=0.0002 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_32_P69368 NA 3398 ENSG00000115738 ID2 
inhibitor of 
DNA binding 
2, dominant 
negative 
helix-loop-
helix protein 
A_23_P151294 NA 3458 ENSG00000111537 IFNG 
interferon, 
gamma 
A_23_P252306 NA 3397 ENSG00000125968 ID1 
inhibitor of 
DNA binding 
1, dominant 
negative 
helix-loop-
helix protein 
 
KEGG pathway : Type I diabetes mellitus  
04940 C=43;O=2;E=0.03;R=60.79;rawP=0.0005;adjP=0.0011 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P151294 NA 3458 ENSG00000111537 IFNG 
interferon, 
gamma 
A_23_P72096 NA 3552 ENSG00000115008 IL1A 
interleukin 1, 
alpha 
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KEGG pathway: Graft-versus-host disease  
05332 C=41;O=2;E=0.03;R=63.75;rawP=0.0005;adjP=0.0011 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P151294 NA 3458 ENSG00000111537 IFNG 
interferon, 
gamma 
A_23_P72096 NA 3552 ENSG00000115008 IL1A 
interleukin 1, 
alpha 
 
KEGG pathway: Melanoma  
05218 C=71;O=2;E=0.05;R=36.81;rawP=0.0014;adjP=0.0028 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_24_P99244 NA 2252 ENSG00000140285 FGF7 
fibroblast 
growth factor 7 
A_23_P93787 NA 3082 ENSG00000019991 HGF 
hepatocyte 
growth factor 
(hepapoietin 
A; scatter 
factor) 
 
KEGG pathway: Chagas disease (American trypanosomiasis) 05142  
C=104;O=2;E=0.08;R=25.13;rawP=0.0029;adjP=0.0048 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P151294 NA 3458 ENSG00000111537 IFNG 
interferon, 
gamma 
A_23_P60306 NA 7099 ENSG00000136869 TLR4 
toll-like 
receptor 4 
 
 
KEGG pathway: Amoebiasis 05146  
C=106;O=2;E=0.08;R=24.66;rawP=0.0030;adjP=0.0048 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P151294 NA 3458 ENSG00000111537 IFNG 
interferon, 
gamma 
A_23_P60306 NA 7099 ENSG00000136869 TLR4 
toll-like 
receptor 4 
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  9.3 Analysis of group C genes 
   9.3.1 Tables showing results of GO analysis 
Biological process: regulation of biological process  
GO:0050789 C=8132;O=70;E=50.58;R=1.38;rawP=1.82e-05;adjP=0.0075 
User Id Value 
Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_24_P14731 NA 27344 ENSG00000102109 PCSK1N 
proprotein 
convertase  
     
subtilisin/kexin 
type 1 inhibitor 
A_24_P113725 NA 6658 ENSG00000134595 SOX3 
SRY (sex 
determining region 
Y)-box 3 
A_24_P213884 NA 7148 ENSG00000168477 TNXB tenascin XB 
A_24_P216165 NA 1050 ENSG00000245848 CEBPA 
CCAAT/enhancer 
binding protein 
(C/EBP), alpha 
A_23_P54573 NA 161882 ENSG00000179588 ZFPM1 
zinc finger protein, 
multitype 1 
A_24_P44916 NA 148170 ENSG00000167617 CDC42EP5 
CDC42 effector 
protein (Rho 
GTPase binding) 5 
A_24_P279060 NA 10021 ENSG00000138622 HCN4 
hyperpolarization 
activated cyclic 
nucleotide-gated 
potassium channel 
4 
A_24_P10674 NA 115703 ENSG00000004777 ARHGAP33 
Rho GTPase 
activating protein 
33 
A_24_P878992 NA 10297 ENSG00000115266 APC2 
adenomatosis 
polyposis coli 2 
A_24_P203315 NA 254263 ENSG00000174871 CNIH2 
cornichon 
homolog 2 
(Drosophila) 
A_24_P251040 NA 9048 ENSG00000117407 ARTN artemin 
A_24_P52882 NA 8739 ENSG00000135116 HRK 
harakiri, BCL2 
interacting protein 
(contains only 
BH3 domain) 
A_23_P109133 NA 551 ENSG00000101200 AVP 
arginine 
vasopressin 
A_24_P269101 NA 4762 ENSG00000181965 NEUROG1 neurogenin 1 
A_32_P74615 NA 389058 ENSG00000204335 SP5 
Sp5 transcription 
factor 
A_24_P34575 NA 5455 ENSG00000198914 POU3F3 Receptor 3 
A_32_P35375 NA 10522 ENSG00000177030 DEAF1 
deformed 
epidermal 
autoregulatory 
factor 1 
(Drosophila) 
 
72 
 
User Id Value 
Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_24_P293089 NA 163033 ENSG00000218891 ZNF579 
zinc finger protein 
579 
A_23_P342612 NA 610 ENSG00000099822 HCN2 
hyperpolarization 
activated cyclic 
nucleotide-gated 
potassium channel 
2 
A_23_P140527 NA 27023 ENSG00000171956 FOXB1 forkhead box B1 
A_24_P144465 NA 63940 ENSG00000213654 GPSM3 
G-protein 
signaling  
A_23_P107394 NA 84667 ENSG00000179111 HES7 
hairy and enhancer 
of split 7 
(Drosophila) 
A_24_P207195 NA 79191 ENSG00000177508 IRX3 
iroquois homeobox 
3 
A_24_P112803 NA 6656 ENSG00000182968 SOX1 
SRY (sex 
determining region 
Y)-box 1 
A_24_P208513 NA 7475 ENSG00000115596 WNT6 
wingless-type 
MMTV integration 
site family, 
member 6 
A_23_P20458 NA 2831 ENSG00000183729 NPBWR1 
neuropeptides B/W 
receptor 1 
A_23_P90189 NA 27113 ENSG00000105327 BBC3 
BCL2 binding 
component 3 
A_24_P57898 NA 128408 ENSG00000125533 BHLHE23 
basic helix-loop-
helix family, 
member e23 
A_24_P923765 NA 399664 ENSG00000181588 MEX3D 
mex-3 homolog D 
(C. elegans) 
A_24_P405992 NA 11346 ENSG00000171992 SYNPO synaptopodin 
A_23_P50773 NA 23373 ENSG00000105662 CRTC1 
CREB regulated 
transcription 
coactivator 1 
A_23_P206466 NA 57524 ENSG00000167971 CASKIN1 
CASK interacting 
protein 1 
A_24_P227326 NA 283248 ENSG00000167771 RCOR2 
REST corepressor 
2 
A_24_P328446 NA 3196 ENSG00000115297 TLX2 
T-cell leukemia 
homeobox 2 
A_24_P117782 NA 85508 ENSG00000215397 SCRT2 
scratch homolog 2, 
zinc finger protein 
(Drosophila) 
A_24_P129107 NA 85409 ENSG00000145506 NKD2 
naked cuticle 
homolog 2 
(Drosophila) 
A_24_P215445 NA 401 ENSG00000165462 PHOX2A 
paired-like 
homeobox 2a 
A_23_P134433 NA 2020 ENSG00000164778 EN2 
engrailed 
homeobox 2 
     motif) receptor 3 
73 
 
A_24_P56689 NA 7755 ENSG00000122386 ZNF205 
zinc finger protein 
205 
A_23_P150162 NA 1815 ENSG00000069696 DRD4 
dopamine receptor 
D4 
A_32_P226918 NA 5586 ENSG00000065243 PKN2 protein kinase N2 
A_23_P150664 NA 387733 ENSG00000206013 IFITM5 interferon induced  
     
transmembrane 
protein 5 
A_24_P173294 NA 83855 ENSG00000129911 KLF16 Kruppel-like factor  
A_24_P266466 NA 2843 ENSG00000204882 GPR20 
G protein-coupled 
receptor 20 
A_23_P15135 NA 84891 ENSG00000130182 ZSCAN10 
zinc finger and 
SCAN domain 
containing 10 
 
  9.3.2 Tables showing results of Transcription Factor analysis 
 
Transcription Target: hsa_CAGGTG_V$E12_Q6 DB_ID:2409 
C=2450;O=30;E=6.70;R=4.48;rawP=2.55e-12;adjP=8.64e-10 
 
User Id Value 
Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_24_P416595 NA 284346 ENSG00000176472 ZNF575 
zinc finger protein 
575 
A_24_P43959 NA 55691 ENSG00000151474 FRMD4A 
FERM domain 
containing 4A 
A_24_P227326 NA 283248 ENSG00000167771 RCOR2 REST corepressor 2 
A_23_P34554 NA 777 ENSG00000198216 CACNA1E 
calcium channel, 
voltage-dependent, 
R type, alpha 1E 
subunit 
A_24_P117782 NA 85508 ENSG00000215397 SCRT2 
scratch homolog 2, 
zinc finger protein 
(Drosophila) 
A_24_P328446 NA 3196 ENSG00000115297 TLX2 
T-cell leukemia 
homeobox 2 
A_24_P113725 NA 6658 ENSG00000134595 SOX3 
SRY (sex 
determining region 
Y)-box 3 
A_23_P96072 NA 2902 ENSG00000176884 GRIN1 
glutamate receptor, 
ionotropic, N-
methyl D-aspartate 
1 
A_24_P215445 NA 401 ENSG00000165462 PHOX2A 
paired-like 
homeobox 2a 
A_24_P218074 NA 168544 ENSG00000181444 ZNF467 
zinc finger protein 
467 
A_23_P140527 NA 27023 ENSG00000171956 FOXB1 forkhead box B1 
A_24_P20807 NA 80758 ENSG00000131188 PRR7 
proline rich 7 
(synaptic) 
A_24_P56689 NA 7755 ENSG00000122386 ZNF205 
zinc finger protein 
205 
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User Id Value 
Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P107394 NA 84667 ENSG00000179111 HES7 
hairy and enhancer 
of split 7 
(Drosophila) 
A_24_P166434 NA 170680 ENSG00000204538 PSORS1C2 
psoriasis 
susceptibility 1 
candidate 2 
A_32_P226918 NA 5586 ENSG00000065243 PKN2 protein kinase N2 
A_23_P25790 NA 64403 ENSG00000139880 CDH24 cadherin 24, type 2 
A_23_P18406 NA 94032 ENSG00000163888 CAMK2N2 
calcium/calmodulin-
dependent protein r  
A_24_P251040 NA 9048 ENSG00000117407 ARTN artemin 
A_24_P208513 NA 7475 ENSG00000115596 WNT6 
wingless-type 
MMTV integration 
site family, member 
6 
A_32_P11425 NA 55752 ENSG00000138758 SEPT11 septin 11 
A_24_P376451 NA 2668 ENSG00000168621 GDNF 
glial cell derived 
neurotrophic factor 
A_24_P61537 NA 1152 ENSG00000166165 CKB 
creatine kinase, 
brain 
A_23_P304530 NA 254910 ENSG00000186207 LCE5A 
late cornified 
envelope 5A 
A_23_P86493 NA 10660 ENSG00000138136 LBX1 
ladybird homeobox 
1 
A_24_P46946 NA 64321 ENSG00000164736 SOX17 
SRY (sex 
determining region 
Y)-box 17 
A_24_P34575 NA 5455 ENSG00000198914 POU3F3 
POU class 3 
homeobox 3 
A_23_P206466 NA 57524 ENSG00000167971 CASKIN1 
CASK interacting 
protein 1 
A_23_P50773 NA 23373 ENSG00000105662 CRTC1 
CREB regulated 
transcription 
coactivator 1 
A_24_P333364 NA 116988 ENSG00000133612 AGAP3 
ArfGAP with 
GTPase domain, 
ankyrin repeat and 
PH domain 3 
 
Transcription Target: hsa_GGGCGGR_V$SP1_Q6 DB_ID:2452 
C=2891;O=27;E=7.91;R=3.41;rawP=1.43e-08;adjP=9.70e-07 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_24_P14731 NA 27344 ENSG00000102109 PCSK1N 
proprotein 
convertase 
subtilisin/kexin 
type 1 inhibitor 
A_24_P416595 NA 284346 ENSG00000176472 ZNF575 
zinc finger protein 
575 
A_24_P117782 NA 85508 ENSG00000215397 SCRT2 
scratch homolog 2, 
zinc finger protein 
(Drosophila) 
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User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_24_P328446 NA 3196 ENSG00000115297 TLX2 
T-cell leukemia 
homeobox 2 
A_24_P215445 NA 401 ENSG00000165462 PHOX2A 
paired-like 
homeobox 2a 
A_24_P216165 NA 1050 ENSG00000245848 CEBPA 
CCAAT/enhancer 
binding protein 
(C/EBP), alpha 
A_24_P218074 NA 168544 ENSG00000181444 ZNF467 
zinc finger protein 
467 
A_23_P140527 NA 27023 ENSG00000171956 FOXB1 forkhead box B1 
A_24_P20807 NA 80758 ENSG00000131188 PRR7 
proline rich 7 
(synaptic) 
 
  9.3.3 Tables showing results of KEGG pathway analysis 
KEGG pathway: Neuroactive ligand-receptor interaction 04080 
C=272;O=6;E=0.74;R=8.06;rawP=0.0001;adjP=0.0014 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P153549 NA 2906 ENSG00000105464 GRIN2D 
glutamate 
receptor, 
ionotropic, N-
methyl D-
aspartate 2D 
A_23_P146885 NA 2837 ENSG00000181408 UTS2R 
urotensin 2 
receptor 
A_23_P150162 NA 1815 ENSG00000069696 DRD4 
dopamine 
receptor D4 
A_23_P20458 NA 2831 ENSG00000183729 NPBWR1 
neuropeptides 
B/W receptor 
1 
A_23_P101761 NA 84634 ENSG00000116014 KISS1R 
KISS1 
receptor 
A_23_P96072 NA 2902 ENSG00000176884 GRIN1 
glutamate 
receptor, 
ionotropic, N-
methyl D-
aspartate 1 
 
KEGG pathway: Wnt signaling pathway 04310 
C=150;O=4;E=0.41;R=9.75;rawP=0.0008;adjP=0.0056 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_24_P208513 NA 7475 ENSG00000115596 WNT6 
wingless-type 
MMTV 
integration 
site family, 
member 6 
A_24_P46946 NA 64321 ENSG00000164736 SOX17 
SRY (sex  
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User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
     
determining 
region Y)-box 
17 
A_24_P878992 NA 10297 ENSG00000115266 APC2 
adenomatosis 
polyposis coli 
2 
A_24_P129107 NA 85409 ENSG00000145506 NKD2 
naked cuticle 
homolog 2 
(Drosophila) 
 
KEGG pathway:  Calcium signaling pathway 04020 
C=177;O=4;E=0.48;R=8.26;rawP=0.0015;adjP=0.0070 
User Id Value Entrez 
ID 
Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P153549 NA 2906 ENSG00000105464 GRIN2D 
glutamate 
receptor, 
ionotropic, 
N-methyl D-
aspartate 2D 
A_24_P399871 NA 8911 ENSG00000100346 CACNA1I 
calcium 
channel, 
voltage-
dependent, T 
type, alpha 
1I subunit 
A_23_P34554 NA 777 ENSG00000198216 CACNA1E 
calcium 
channel, 
voltage-
dependent, R 
type, alpha 
1E subunit 
A_23_P96072 NA 2902 ENSG00000176884 GRIN1 
glutamate 
receptor, 
ionotropic, 
N-methyl D-
aspartate 1 
 
KEGG pathway: Basal cell carcinoma 05217 
C=55;O=2;E=0.15;R=13.29;rawP=0.0100;adjP=0.0280 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_24_P208513 NA 7475 ENSG00000115596 WNT6 
wingless-type 
MMTV 
integration 
site family, 
member 6 
A_24_P878992 NA 10297 ENSG00000115266 APC2 
adenomatosis 
polyposis coli 
2 
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KEGG pathway: Amyotrophic lateral sclerosis (ALS) 05014 
C=53;O=2;E=0.15;R=13.79;rawP=0.0093;adjP=0.0280 
 
User Id Value Entrez ID Ensembl Gene 
Stable ID 
Gene 
Symbol 
Description 
A_23_P153549 NA 2906 ENSG00000105464 GRIN2D 
glutamate 
receptor,  
     
ionotropic, 
N-methyl D-
aspartate 2D 
A_23_P96072 NA 2902 ENSG00000176884 GRIN1 
glutamate 1 
receptor, 
ionotropic, 
N-methyl D-
aspartate 
 
 
